LURASIDONE HYDROCHLORIDE- lurasidone hydrochloride tablet, film coated Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LURASIDONE HYDROCHLORIDE TABLETS safely and effectively. See full prescribing information for LURASIDONE HYDROCHLORIDE TABLETS. LURASIDONE hydrochloride tablets, for oral use Initial U.S. Approval: 2010

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS and BEHAVIORS See full prescribing information for complete boxed warning.

- Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Lurasidone hydrochloride tablet is not approved for the treatment of patients with dementia-related psychosis (5.1).
- Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients. Closely monitor for clinical worsening and emergence of suicidal thoughts and behaviors. (5.2).

INDICATIONS AND USAGE

Lurasidone hydrochloride is an atypical antipsychotic indicated for the treatment of:

- Schizophrenia in adults and adolescents (13 to 17 years) (1, 14.1)
- Depressive episode associated with Bipolar I Disorder (bipolar depression) in adults and pediatric patients (10 to 17 years) as monotherapy (1, 14.2)
- Depressive episode associated with Bipolar I Disorder (bipolar depression) in adults as adjunctive therapy with lithium or valproate (1, 14.2)

DOSAGE AND ADMINISTRATION

Lurasidone hydrochloride tablets should be taken with food (at least 350 calories). Administration with food substantially increases the absorption of lurasidone (2.3, 12.3).

Indication	Starting Dose	Recommended Dose
Schizophrenia – adults (2.1)	40 mg per day	40 mg to 160 mg per day
Schizophrenia adolescents (13 to 17 years) (2.1)	40 mg per day	40 mg to 80 mg per day
Bipolar Depression adults (2.2)	20 mg per day	20 mg to 120 mg per day
Bipolar Depression pediatric patients (10 to 17 years) (2.2)	20 mg per day	20 mg to 80 mg per day

- <u>Moderate and Severe Renal Impairment:</u> Recommended starting dose is 20 mg per day, and the maximum recommended dose is 80 mg per day (2.4, 8.6).
- <u>Moderate and Severe Hepatic Impairment:</u> Recommended starting dose is 20 mg per day. The maximum recommended dose is 80 mg per day in moderate hepatic impairment and 40 mg per day in severe hepatic impairment (2.5, 8.7).
- <u>Concomitant Use of a Moderate CYP3A4 inhibitor (e.g., diltiazem)</u>: Lurasidone hydrochloride tablets dose should be reduced to half of the original dose level. Recommended starting dose is 20 mg per day. Maximum recommended dose is 80 mg per day (2.6, 7.1).
- <u>Concomitant Use of a Moderate CYP3A4 Inducer</u>: It may be necessary to increase the dose of lurasidone hydrochloride tablets (2.6, 7.1).

Tablets: 20 mg, 40 mg, 60 mg, 80 mg, 120 mg (3)
• Known hypersensitivity to lurasidone hydrochloride or any components in the formulation (4).

- Concomitant use with a strong CYP3A4 inhibitor (e.g., ketoconazole) (2.6, 4, 7.1).
- Concomitant use with a strong CYP3A4 inducer (e.g., rifampin) (2.6, 4, 7.1).

WARNINGS AND PRECAUTIONS

- <u>Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis:</u> Increased incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack) (5.3).
- <u>Neuroleptic Malignant Syndrome</u>: Manage with immediate discontinuation and close monitoring (5.4).
- <u>Tardive Dyskinesia</u>: Discontinue if clinically appropriate (5.5).
- <u>Metabolic Changes</u>: Monitor for hyperglycemia/diabetes mellitus, dyslipidemia and weight gain (5.6).

- <u>Hyperprolactinemia</u>: Prolactin elevations may occur (5.7).
- <u>Leukopenia, Neutropenia, and Agranulocytosis:</u> Perform complete blood counts (CBC) in patients with a pre-existing low white blood cell count (WBC) or a history of leukopenia or neutropenia. Consider discontinuing lurasidone hydrochloride tablets if a clinically significant decline in WBC occurs in the absence of other causative factors (5.8).
- Orthostatic Hypotension and Syncope: Monitor heart rate and blood pressure and warn patients with known cardiovascular or cerebrovascular disease, and risk of dehydration or syncope (5.9).

ADVERSE REACTIONS

Commonly observed adverse reactions (incidence \geq 5% and at least twice the rate for placebo) were (6.1):

- Adult patients with schizophrenia: somnolence, akathisia, extrapyramidal symptoms, and nausea
- Adolescent patients (13 to 17 years) with schizophrenia: somnolence, nausea, akathisia, EPS (non-akathisia), rhinitis (80 mg only), and vomiting
- Adult patients with bipolar depression: akathisia, extrapyramidal symptoms, and somnolence
- Pediatric patients (10 to 17 years) with bipolar depression: nausea, weight increase, and insomnia.

To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

------USE IN SPECIFIC POPULATIONS

• <u>Pregnancy</u>: May cause extrapyramidal and or/withdrawal symptoms in neonates with third trimester exposure (8.1).

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 3/2025

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS and BEHAVIORS 1 INDICATIONS AND USAGE

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Schizophrenia
- 2.2 Depressive Episodes Associated with Bipolar I Disorder
- 2.3 Administration Information
- 2.4 Dose Modifications for Renal Impairment
- 2.5 Dose Modifications for Hepatic Impairment

2.6 Dose Modifications Due to Drug Interactions of CYP3A4 Inhibitors and CYP3A4 Inducers

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

- 5.2 Suicidal Thoughts and Behaviors in Pediatric and Young Adult Patients
- 5.3 Cerebrovascular Adverse Reactions, Including Stroke in Elderly

Patients with Dementia-Related Psychosis

- 5.4 Neuroleptic Malignant Syndrome
- 5.5 Tardive Dyskinesia
- 5.6 Metabolic Changes
- 5.7 Hyperprolactinemia
- 5.8 Leukopenia, Neutropenia and Agranulocytosis
- 5.9 Orthostatic Hypotension and Syncope
- 5.10 Falls
- 5.11 Seizures
- 5.12 Potential for Cognitive and Motor Impairment
- 5.13 Body Temperature Dysregulation
- 5.14 Activation of Mania/Hypomania
- 5.15 Dysphagia

5.16 Neurological Adverse Reactions in Patients with Parkinson's Disease or Dementia with Lewy Bodies

- **6 ADVERSE REACTIONS**
 - 6.1 Clinical Trials Experience
 - 6.2 Postmarketing Experience
- **7 DRUG INTERACTIONS**
 - 7.1 Drugs Having Clinically Important Interactions with Lurasidone
 - 7.2 Drugs Having No Clinically Important Interactions with Lurasidone
- **8 USE IN SPECIFIC POPULATIONS**
 - 8.1 Pregnancy
 - 8.2 Lactation
 - 8.4 Pediatric Use
 - 8.5 Geriatric Use
 - 8.6 Renal Impairment
 - 8.7 Hepatic Impairment
- 8.8 Other Specific Populations
- 9 DRUG ABUSE AND DEPENDENCE
 - 9.1 Controlled Substance
 - 9.2 Abuse
- **10 OVERDOSAGE**
- 10.1 Human Experience
- 10.2 Management of Overdosage
- **11 DESCRIPTION**
- **12 CLINICAL PHARMACOLOGY**
 - 12.1 Mechanism of Action
 - **12.2 Pharmacodynamics**
 - 12.3 Pharmacokinetics
- **13 NONCLINICAL TOXICOLOGY**
 - 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- **14 CLINICAL STUDIES**
 - 14.1 Schizophrenia
- 14.2 Depressive Episodes Associated with Bipolar I Disorder
- **16 HOW SUPPLIED/STORAGE AND HANDLING**

17 PATIENT COUNSELING INFORMATION

 \ast Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS and BEHAVIORS

Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Lurasidone hydrochloride tablets are not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1)].

Suicidal Thoughts and Behaviors

Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adults in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors. [see Warnings and Precautions (5.2)].

1 INDICATIONS AND USAGE

Lurasidone hydrochloride tablet is indicated for:

- Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see *Clinical Studies (14.1)*].
- Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies (14.2)].
- Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies (14.2)].

2 DOSAGE AND ADMINISTRATION

2.1 Schizophrenia

Adults

The recommended starting dose of lurasidone hydrochloride tablet is 40 mg once daily. Initial dose titration is not required. Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 40 mg per day to 160 mg per day [*see Clinical Studies* (14.1)]. The maximum recommended dose is 160 mg per day.

Adolescents (13 to 17 years)

The recommended starting dose of lurasidone hydrochloride tablet is 40 mg once daily. Initial dose titration is not required. Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 40 mg per day to 80 mg per day [*see Clinical Studies* (14.1)]. The maximum recommended dose is 80 mg per day.

2.2 Depressive Episodes Associated with Bipolar I Disorder

Adults

The recommended starting dose of lurasidone hydrochloride tablet is 20 mg given once daily as monotherapy or as adjunctive therapy with lithium or valproate. Initial dose titration is not required. Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 20 mg per day to 120 mg per day as monotherapy or as adjunctive therapy with lithium or valproate [*see Clinical Studies (14.2)*]. The maximum recommended dose, as monotherapy or as adjunctive therapy with lithium or valproate, is 120 mg per day. In the monotherapy study, the higher dose range (80 mg to 120 mg per day) did not provide additional efficacy, on average, compared to the lower dose range (20 to 60 mg per day) [*see Clinical Studies (14.2)*].

Pediatric Patients (10 to 17 years)

The recommended starting dose of lurasidone hydrochloride tablet is 20 mg given once daily as monotherapy. Initial dose titration is not required. The dose may be increased after one week based on clinical response. Lurasidone hydrochloride tablets have been shown to be effective in a dose range of 20 mg per day to 80 mg per day as monotherapy. At the end of the clinical study, most of the patients (67%) received 20 mg or 40 mg once daily *[see Clinical Studies (14.2)]*. The maximum recommended dose is 80 mg per day.

The efficacy of lurasidone hydrochloride tablets in the treatment of mania associated with bipolar disorder has not been established.

2.3 Administration Information

Lurasidone hydrochloride tablets should be taken with food (at least 350 calories). Administration with food substantially increases the absorption of lurasidone. Administration with food increases the AUC approximately 2-fold and increases the C_{max} approximately 3-fold. In the clinical studies, lurasidone hydrochloride tablets were administered with food [see Clinical Pharmacology (12.3)].

The effectiveness of lurasidone hydrochloride tablets for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use lurasidone hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2.1 and 2.2)].

2.4 Dose Modifications for Renal Impairment

Dose adjustment is recommended in moderate (creatinine clearance: 30 to <50 mL/min) and severe renal impairment (creatinine clearance <30 mL/min) patients. The recommended starting dose is 20 mg per day. The dose in these patients should not exceed 80 mg per day [see Use in Specific Populations (8.6)].

2.5 Dose Modifications for Hepatic Impairment

Dose adjustment is recommended in moderate (Child-Pugh Score = 7 to 9) and severe hepatic impairment (Child-Pugh Score = 10 to 15) patients. The recommended starting dose is 20 mg per day. The dose in moderate hepatic impairment patients should not exceed 80 mg per day and the dose in severe hepatic impairment patients should not exceed 40 per mg/day [see Use in Specific Populations (8.7)].

2.6 Dose Modifications Due to Drug Interactions of CYP3A4 Inhibitors and CYP3A4 Inducers

Concomitant Use with CYP3A4 Inhibitors

Lurasidone hydrochloride tablets should not be used concomitantly with a strong CYP3A4 inhibitor (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) [see Contraindications (4)].

If lurasidone hydrochloride tablets are being prescribed and a moderate CYP3A4 inhibitor (e.g. diltiazem, atazanavir, erythromycin, fluconazole, verapamil etc.) is added to the therapy, the lurasidone hydrochloride tablets dose should be reduced to half of the original dose level. Similarly, if a moderate CYP3A4 inhibitor is being prescribed and lurasidone hydrochloride tablets are added to the therapy, the recommended starting dose of lurasidone hydrochloride tablets is 20 mg per day, and the maximum recommended dose of lurasidone hydrochloride tablets is 80 mg per day [see Contraindications (4), Drug Interactions (7.1)].

Grapefruit and grapefruit juice should be avoided in patients taking lurasidone hydrochloride tablets, since these may inhibit CYP3A4 and alter lurasidone concentrations [*see Drug Interactions (7.1*)].

Concomitant Use with CYP3A4 Inducers

Lurasidone hydrochloride tablets should not be used concomitantly with a strong CYP3A4 inducer (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Contraindications (4); Drug Interactions (7.1)]. If lurasidone hydrochloride tablets are used concomitantly with a moderate CYP3A4 inducer, it may be necessary to increase the lurasidone hydrochloride tablets dose after chronic treatment (7 days or more) with the CYP3A4 inducer.

3 DOSAGE FORMS AND STRENGTHS

Lurasidone hydrochloride tablets are available in the following shape and color (Table 1) with respective one-sided debossing.

Tablet Strength	Tablet Color/Shape	Tablet Markings
20 mg	white to off-white round	Debossed "335" on one side
	shape	and plain on the reverse side.
40 mg	white to off-white round	Debossed "336" on one side
	shape	and plain on the reverse side.
60 mg	white to off-white capsule	Debossed "337" on one side
	shape	and plain on reverse side.
80 mg	white to off-white oval shape	e Debossed "338" on one side
		and plain on the reverse side.
120 mg	white to off-white oval shape	e Debossed "339" on one side
		and plain on reverse side.

Table 1: Lurasidone Hydrochloride Tablet Presentations

4 CONTRAINDICATIONS

- Known hypersensitivity to lurasidone HCl or any components in the formulation. Angioedema has been observed with lurasidone [see Adverse Reactions (6.1)].
- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) [see Drug Interactions (7.1)].
- Strong CYP3A4 inducers (e.g., rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine, etc.) [see Drug Interactions (7.1)].

5 WARNINGS AND PRECAUTIONS

5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6- to 1.7-times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drugtreated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. Lurasidone hydrochloride tablets are not approved for the treatment of patients with dementia-related psychosis [see Boxed Warning, Warnings and Precautions (5.3)].

5.2 Suicidal Thoughts and Behaviors in Pediatric and Young Adult Patients

In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients, and over 4,400 pediatric patients, the incidence of suicidal thoughts and behaviors in pediatric and young adult patients was greater in antidepressant-treated patients than in placebo-treated patients. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1,000 patients treated are provided in Table 2.

No suicides occurred in any of the pediatric studies. There were suicides in the adult studies, but the number was not sufficient to reach any conclusion about antidepressant drug effect on suicide.

Table 2: Risk Differences of the Number of Cases of Suicidal Thoughts orBehaviors in the Pooled Placebo-Controlled Trials of Antidepressants inPediatric and Adult Patients

Age Range	Drug-Placebo Difference in Number of Patients of Suicidal Thoughts or Behaviors per 1,000 Patients Treated		
	Increases Compared to Placebo		
<18	14 additional patients		
18 to 24	5 additional patients		
	Decreases Compared to Placebo		
25 to 64	1 fewer patient		
≥65	6 fewer patients		

It is unknown whether the risk of suicidal thoughts and behaviors in pediatric and young adult patients extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance studies in adults with MDD that antidepressants delay the recurrence of depression.

Monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing lurasidone hydrochloride tablets, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.

5.3 Cerebrovascular Adverse Reactions, Including Stroke in Elderly Patients with Dementia-Related Psychosis

In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), including fatalities, compared to placebo-treated subjects. Lurasidone hydrochloride tablets are not approved for the treatment of patients with dementia-related psychosis [see Boxed Warning, Warnings and Precautions (5.1)].

5.4 Neuroleptic Malignant Syndrome

A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant

Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including lurasidone. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability. Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure.

If NMS is suspected, immediately discontinue lurasidone hydrochloride tablets and provide intensive symptomatic treatment and monitoring.

5.5 Tardive Dyskinesia

Tardive dyskinesia is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements that can develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.

The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses or may even arise after discontinuation of treatment.

The syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.

Given these considerations, lurasidone hydrochloride tablets should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.

If signs and symptoms of tardive dyskinesia appear in a patient on lurasidone hydrochloride tablets, drug discontinuation should be considered. However, some patients may require treatment with lurasidone hydrochloride tablets despite the presence of the syndrome.

5.6 Metabolic Changes

Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain. While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.

Hyperglycemia and Diabetes Mellitus

Hyperglycemia, in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of diabetes mellitus in patients with schizophrenia and the increasing incidence of diabetes mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and hyperglycemia-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of hyperglycemia-related adverse events in patients treated with the atypical antipsychotics.

Patients with an established diagnosis of diabetes mellitus who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients with risk factors for diabetes mellitus (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect drug.

Schizophrenia

<u>Adults</u>

Pooled data from short-term, placebo-controlled schizophrenia studies are presented in Table 3.

				idone ide Tablets		
	Placebo	20 mg/day	40 mg/day	80 mg/day	120 mg/day	160 mg/day
	Me	an Chang	ge from Base	eline (mg/dl	_)	
	n=680	n=71	n=478	n=508	n=283	n=113
Serum Glucose	-0.0	-0.6	+2.6	-0.4	+2.5	+2.5
	Proportio	n of Patie	ents with Sh	ifts to ≥ 12	6 mg/dL	
Serum	8.3%	11.7%	12.7%	6.8%	10.0%	5.6%
Glucose $(\geq 126 \text{ mg/dL})$	(52/628)	(7/60)	(57/449)	(32/472)	(26/260)	(6/108)

Table 3: Change in Fasting Glucose in Adult Schizophrenia Studies

In the uncontrolled, longer-term schizophrenia studies (primarily open-label extension studies), lurasidone hydrochloride tablets were associated with a mean change in glucose of +1.8 mg/dL at week 24 (n=355), +0.8 mg/dL at week 36 (n=299) and +2.3 mg/dL at week 52 (n=307).

<u>Adolescents</u>

In studies of adolescents and adults with schizophrenia, changes in fasting glucose were similar. In the short-term, placebo-controlled study of adolescents, fasting serum glucose mean values were -1.3 mg/dL for placebo (n=95), +0.1 mg/dL for 40 mg/day (n=90), and +1.8 mg/dL for 80 mg/day (n=92).

Bipolar Depression

<u>Adults</u>

Monotherapy

Data from the adult short-term, flexible-dose, placebo-controlled monotherapy bipolar

		Lurasidone Hydroc	hloride Tablets
	Placebo	20 to 60 mg/day	80 to 120 mg/day
	Mean Change from	Baseline (mg/dL)	
	n=148	n=140	n=143
Serum Glucose	+1.8	-0.8	+1.8
Proport	tion of Patients wit	h Shifts to \geq 126 mg/	dL
Serum Glucose	4.3%	2.2%	6.4%
(≥126 mg/dL)	(6/141)	(3/138)	(9/141)

Table 4: Change in Fasting Glucose in the Adult Monotherapy BipolarDepression Study

Patients were randomized to flexibly dosed lurasidone hydrochloride tablets 20 to 60 mg/day, lurasidone hydrochloride tablets 80 to 120 mg/day, or placebo.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received lurasidone hydrochloride tablets as monotherapy in the short-term study and continued in the longer-term study, had a mean change in glucose of +1.2 mg/dL at week 24 (n=129).

Adjunctive Therapy with Lithium or Valproate

Data from the adult short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies are presented in Table 5.

Table 5: Change in Fasting Glucose in the Adult Adjunctive Therapy BipolarDepression Studies

	Placebo	Lurasidone Hydrochloride Tablets 20 to 120 mg/day	
Mean	Change from Baseline (r	ng/dL)	
	n=302	n=319	
Serum Glucose	-0.9	+1.2	
Proportion o	of Patients with Shifts to	≥ 126 mg/dL	
Serum Glucose	1.0%	1.3%	
(≥ 126 mg/dL)	(3/290)	(4/316)	

Patients were randomized to flexibly dosed lurasidone hydrochloride tablets 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received lurasidone hydrochloride tablets as adjunctive therapy with either lithium or valproate in the short-term study and continued in the longer-term study, had a mean change in glucose of +1.7 mg/dL at week 24 (n=88).

Pediatric Patients (10 to 17 years)

In studies of pediatric patients 10 to 17 years and adults with bipolar depression, changes in fasting glucose were similar. In the 6-week, placebo-controlled study of pediatric patients with bipolar depression, mean change in fasting glucose was +1.6 mg/dL for lurasidone hydrochloride tablets 20 to 80 mg/day (n=145) and -0.5 mg/dL for placebo (n=145).

Pediatric Patients (6 to 17 years)

In a 104-week, open-label study in pediatric patients with schizophrenia, bipolar depression, or autistic disorder, 7 % of patients with a normal baseline fasting glucose experienced a shift to high at endpoint while taking lurasidone.

<u>Dyslipidemia</u>

Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.

Schizophrenia

<u>Adults</u>

Pooled data from short-term, placebo-controlled schizophrenia studies are presented in Table 6: Change in Fasting Lipids in Adult Schizophrenia Studies

				idone ide Tablets		
	Placebo	20 mg/day	40 mg/day	80 mg/day	120 mg/day	160 mg/day
	Me	an Chang	je from Bas	eline (mg/dL)	
	n=660	n=71	n=466	n=499	n=268	n=115
Total	-5.8	-12.3	-5.7	-6.2	-3.8	-6.9
Cholesterol						
Triglycerides	-13.4	-29.1	-5.1	-13.0	-3.1	-10.6
	Ρ	roportion	of Patients	with Shifts		
Total	5.3%	13.8%	6.2%	5.3%	3.8%	4.0%
Cholesterol (≥	(30/571)	(8/58)	(25/402)	(23/434)	(9/238)	(4/101)
240 mg/dL)						
Triglycerides	10.1%	14.3%	10.8%	6.3%	10.5%	7.0%
(≥ 200 mg/dL)	(53/526)	(7/49)	(41/379)	(25/400)	(22/209)	(7/100)

Table 6: Change in Fasting Lipids in Adult Schizophrenia Studies

In the uncontrolled, longer-term schizophrenia studies (primarily open-label extension studies), lurasidone hydrochloride tablets were associated with a mean change in total cholesterol and triglycerides of -3.8 (n=356) and -15.1 (n=357) mg/dL at week 24, -3.1 (n=303) and -4.8 (n=303) mg/dL at week 36 and -2.5 (n=307) and -6.9 (n=307) mg/dL at week 52, respectively.

<u>Adolescents</u>

In the adolescent short-term, placebo-controlled study, fasting serum cholesterol mean values were -9.6 mg/dL for placebo (n=95), -4.4 mg/dL for 40 mg/day (n=89), and +1.6 mg/dL for 80 mg/day (n=92), and fasting serum triglyceride mean values were +0.1 mg/dL for placebo (n=95), -0.6 mg/dL for 40 mg/day (n=89), and +8.5 mg/dL for 80 mg/day (n=92).

Bipolar Depression

<u>Adults</u>

Monotherapy

Data from the adult short-term, flexible-dosed, placebo-controlled, monotherapy bipolar depression study are presented in Table 7.

Table 7: Change in Fasting Lipids in the Adult Monotherapy BipolarDepression Study

	Lurasidone Hydro	Lurasidone Hydrochloride Tablets		
Placebo	20 to 60 mg/day	80 to 120 mg/day		
Mean Change	from Baseline (mg/dL)			
n=147	n=140	n=144		
-3.2	+1.2	-4.6		
+6.0	+5.6	+0.4		
Proportion of	f Patients with Shifts			
4.2%	4.4%	4.4%		
(5/118)	(5/113)	(5/114)		
4.8%	10.1%	9.8%		
(6/126)	(12/119)	(12/122)		
	Mean Change n=147 -3.2 +6.0 Proportion of 4.2% (5/118) 4.8%	Placebo 20 to 60 mg/day Mean Change from Baseline (mg/dL) n=147 n=140 -3.2 +1.2 +6.0 +5.6 Proportion of Patients with Shifts 4.2% 4.4% (5/118) (5/113) 4.8% 10.1%		

. .

.....

Patients were randomized to flexibly dosed lurasidone hydrochloride tablets 20 to 60 mg/day, lurasidone hydrochloride tablets 80 to 120 mg/day, or placebo

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received lurasidone hydrochloride tablets as monotherapy in the short-term and continued in the longer-term study had a mean change in total cholesterol and triglycerides of -0.5 mg/dL (n=130) and -1.0 mg/dL (n=130) at week 24, respectively.

Adjunctive Therapy with Lithium or Valproate

Data from the adult short-term, flexible-dosed, placebo-controlled, adjunctive therapy bipolar depression studies are presented in Table 8.

		Lurasidone Hydrochloride Tablets	
	Placebo	20 to 120 mg/day	
	Mean Change from B	aseline (mg/dL)	
	n=303	n=321	
Total	-2.9	-3.1	
Cholesterol			
Triglycerides	-4.6	+4.6	
	Proportion of Patier	its with Shifts	
Total	5.7%	5.4%	
Cholesterol	(15/263)	(15/276)	
(≥ 240 mg/dL)			
Triglycerides	8.6%	10.8%	
(≥200 mg/dL)	(21/243)	(28/260)	

Table 8: Change in Fasting Lipids in the Adult Adjunctive Therapy BipolarDepression Studies

Patients were randomized to flexibly dosed lurasidone hydrochloride tablets 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received lurasidone hydrochloride tablets, as adjunctive therapy with either lithium or valproate in the short-term study and continued in the longer-term study, had a mean change in total cholesterol and triglycerides of -0.9 (n=88) and +5.3 (n=88) mg/dL at week 24, respectively.

Pediatric Patients (10 to 17 years)

In the 6-week, placebo-controlled bipolar depression study with pediatric patients 10 to 17 years, mean change in fasting cholesterol was -6.3 mg/dL for lurasidone

hydrochloride tablets 20 to 80 mg/day (n=144) and -1.4 mg/dL for placebo (n=145), and mean change in fasting triglyceride was -7.6 mg/dL for lurasidone hydrochloride tablets 20 to 80 mg/day (n=144) and +5.9 mg/dL for placebo (n=145).

Pediatric Patients (6 to 17 years)

In a 104-week, open-label study of pediatric patients with schizophrenia, bipolar depression, or autistic disorder, shifts in baseline fasting cholesterol from normal to high at endpoint were reported in 12% (total cholesterol), 3% (LDL cholesterol), and shifts in baseline from normal to low were reported in 27% (HDL cholesterol) of patients taking lurasidone. Of patients with normal baseline fasting triglycerides, 12% experienced shifts to high.

<u>Weight Gain</u>

Weight gain has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.

Schizophrenia

<u>Adults</u>

Pooled data from short-term, placebo-controlled schizophrenia studies are presented in Table 9. The mean weight gain was +0.43 kg for lurasidone hydrochloride tablets-treated patients compared to -0.02 kg for placebo-treated patients. Change in weight from baseline for olanzapine was +4.15 kg and for quetiapine extended-release was +2.09 kg in Studies 3 and 5 [see Clinical Studies (14.1)], respectively. The proportion of patients with a \geq 7% increase in body weight (at Endpoint) was 4.8% for lurasidone hydrochloride tablets-treated patients and 3.3% for placebo-treated patients.

Table 9: Mean Change in Weight (kg) from Baseline in Adult SchizophreniaStudies

	Lurasidone Hydrochloride Tablets					
	Placebo (n=696)	20 mg/day (n=71)	40 mg/day (n=484)	80 mg/day (n=526)	120 mg/day (n=291)	160 mg/day (n=114)
All Patients	-0.02	-0.15	+0.22	+0.54	+0.68	+0.60

In the uncontrolled, longer-term schizophrenia studies (primarily open-label extension studies), lurasidone hydrochloride tablets were associated with a mean change in weight of -0.69 kg at week 24 (n=755), -0.59 kg at week 36 (n=443) and -0.73 kg at week 52 (n=377).

Adolescents

Data from the short-term, placebo-controlled adolescent schizophrenia study are presented in Table 10. The mean change in weight gain was +0.5 kg for lurasidone hydrochloride tablets-treated patients compared to +0.2 kg for placebo-treated patients. The proportion of patients with a \geq 7% increase in body weight (at Endpoint) was 3.3% for lurasidone hydrochloride tablets-treated patients and 4.5% for placebotreated patients.

Table 10: Mean Change in Weight (kg) from Baseline in the AdolescentSchizophrenia Study

	Lurasidone Hydrochloride Tablets		
Placebo	40 mg/day	80 mg/day	
(n=111)	(n=109)	(n=104)	

All Patients	+0.2	+0.3	+0.7
			•

Bipolar Depression

<u>Adults</u>

Monotherapy

Data from the adult short-term, flexible-dosed, placebo-controlled monotherapy bipolar depression study are presented in Table 11. The mean change in weight gain was +0.29 kg for lurasidone hydrochloride tablets-treated patients compared to -0.04 kg for placebo-treated patients. The proportion of patients with a \geq 7% increase in body weight (at Endpoint) was 2.4% for lurasidone hydrochloride tablets-treated patients and 0.7% for placebo-treated patients.

Table 11: Mean Change in Weight (kg) from Baseline in the AdultMonotherapy Bipolar Depression Study

	Lurasidone Hydrochloride Tablets			
Placebo (n=151)	20 to 60 mg/day (n=143)	80 to 120 mg/day (n=147)		
-0.04	+0.56	+0.02		
	(n=151)	Placebo 20 to 60 mg/day (n=151) (n=143)		

Patients were randomized to flexibly dosed lurasidone hydrochloride tablets 20 to 60 mg/day, lurasidone hydrochloride tablets 80 to 120 mg/day, or placebo

In the uncontrolled, open-label, longer-term bipolar depression study, patients who received lurasidone hydrochloride tablets as monotherapy in the short-term and continued in the longer-term study had a mean change in weight of -0.02 kg at week 24 (n=130).

Adjunctive Therapy with Lithium or Valproate

Data from the adult short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies are presented in Table 12. The mean change in weight gain was +0.11 kg for lurasidone hydrochloride tablets-treated patients compared to +0.16 kg for placebo-treated patients. The proportion of patients with a \geq 7% increase in body weight (at Endpoint) was 3.1% for lurasidone hydrochloride tablets-treated patients and 0.3% for placebo-treated patients.

Table 12: Mean Change in Weight (kg) from Baseline in the Adult AdjunctiveTherapy Bipolar Depression Studies

	Lurasidone Hydrochloride Tablets
Placebo	20 to 120 mg/day
(n=307)	(n=327)
+0.16	+0.11
	(n=307)

Patients were randomized to flexibly dosed lurasidone hydrochloride tablets 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate

In the uncontrolled, open-label, longer-term bipolar depression study, patients who were treated with lurasidone hydrochloride tablets, as adjunctive therapy with either lithium or valproate in the short-term and continued in the longer-term study, had a mean change in weight of +1.28 kg at week 24 (n=86).

Pediatric Patients (10 to 17 years)

Data from the 6-week, placebo-controlled bipolar depression study in patients 10 to 17

years are presented in Table 13. The mean change in weight gain was +0.7 kg for lurasidone hydrochloride tablets-treated patients compared to +0.5 kg for placebo-treated patients. The proportion of patients with a \geq 7% increase in body weight (at Endpoint) was 4.0% for lurasidone hydrochloride tablets-treated patients and 5.3% for placebo-treated patients.

		Lurasidone Hydrochloride Tablets
	Placebo	20 to 80 mg/day
	(n=170)	(n=175)
All Patients	+0.5	+0.7

Table 13: Mean Change in Weight (kg) from Baseline in the Bipolar Depression Study in Pediatric Patients (10 to 17 years)

Pediatric Patients (6 to 17 years)

In a long-term, open-label study that enrolled pediatric patients with schizophrenia, bipolar depression, or autistic disorder from three short-term, placebo-controlled trials, 54% (378/701) received lurasidone for 104 weeks. The mean increase in weight from open-label baseline to Week 104 was 5.85 kg. To adjust for normal growth, z-scores were derived (measured in standard deviations [SD]), which normalize for the natural growth of children and adolescents by comparisons to age- and sex-matched population standards. A z-score change <0.5 SD is considered not clinically significant. In this trial, the mean change in z-score from open-label baseline to Week 104 was -0.06 SD for body weight and -0.13 SD for body mass index (BMI), indicating minimal deviation from the normal curve for weight gain.

5.7 Hyperprolactinemia

As with other drugs that antagonize dopamine D2 receptors, lurasidone elevates prolactin levels. Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotrophin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. Galactorrhea, amenorrhea, gynecomastia, and impotence have been reported with prolactin-elevating compounds. Long-standing hyperprolactinemia, when associated with hypogonadism, may lead to decreased bone density in both female and male patients *[see Adverse Reactions (6)]*.

Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent *in vitro*, a factor of potential importance if the prescription of these drugs is considered in a patient with previously detected breast cancer. As is common with compounds which increase prolactin release, an increase in mammary gland neoplasia was observed in a carcinogenicity study conducted with lurasidone in rats and mice [see Nonclinical Toxicology (13)]. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans, but the available evidence is too limited to be conclusive.

Schizophrenia

<u>Adults</u>

In short-term, placebo-controlled schizophrenia studies, the median change from baseline to endpoint in prolactin levels for lurasidone hydrochloride tablets-treated patients was +0.4 ng/mL and was -1.9 ng/mL in the placebo-treated patients. The median change from baseline to endpoint for males was +0.5 ng/mL and for females was -0.2 ng/mL. Median changes for prolactin by dose are shown in Table 14.

Table 14: Median Change in Prolactin (ng/mL) from Baseline in Adult Schizophrenia Studies

	Lurasidone Hydrochloride Tablets							
	Placebo	20 mg/day	40 mg/day	80 mg/day	120 mg/day	160 mg/day		
All Patients	-1.9	-1.1	-1.4	-0.2	+3.3	+3.3		
	(n=672)	(n=70)	(n=476)	(n=495)	(n=284)	(n=115)		
Females	-5.1	-0.7	-4.0	-0.2	+6.7	+7.1		
	(n=200)	(n=19)	(n=149)	(n=150)	(n=70)	(n=36)		
Males	-1.3	-1.2	-0.7	-0.2	+3.1	+2.4		
	(n=472)	(n=51)	(n=327)	(n=345)	(n=214)	(n=79)		

The proportion of patients with prolactin elevations $\geq 5 \times$ upper limit of normal (ULN) was 2.8% for lurasidone hydrochloride tablets-treated patients and = 1.0% for placebotreated patients. The proportion of female patients with prolactin elevations $\geq 5 \times$ ULN was 5.7% for lurasidone hydrochloride tablets-treated patients and = 2.0% for placebotreated female patients. The proportion of male patients with prolactin elevations $\geq 5 \times$ ULN was 1.6% and 0.6% for placebo-treated male patients.

In the uncontrolled longer-term schizophrenia studies (primarily open-label extension studies), lurasidone hydrochloride tablets were associated with a median change in prolactin of -0.9 ng/mL at week 24 (n=357), -5.3 ng/mL at week 36 (n=190) and -2.2 ng/mL at week 52 (n=307).

<u>Adolescents</u>

In the short-term, placebo-controlled adolescent schizophrenia study, the median change from baseline to endpoint in prolactin levels for lurasidone hydrochloride tablets-treated patients was +1.1 ng/mL and was +0.1 ng/mL for placebo-treated patients. For lurasidone hydrochloride tablets-treated patients, the median change from baseline to endpoint for males was +1.0 ng/mL and for females was +2.6 ng/mL. Median changes for prolactin by dose are shown in Table 15.

	Placebo	Lurasidone Hydrochloride Tablets 40 mg/day	Lurasidone Hydrochloride Tablets 80 mg/day	
All Patients	+0.10	+0.75	+1.20	
	(n=103)	(n=102)	(n=99)	
Females	+0.70	+0.60	+4.40	
	(n=39)	(n=42)	(n=33)	
Males	0.00	+0.75	+1.00	
	(n=64)	(n=60)	(n=66)	

Table 15: Median Change in Prolactin (ng/mL) from Baseline in the AdolescentSchizophrenia Study

The proportion of patients with prolactin elevations $\geq 5x$ ULN was 0.5% for lurasidone hydrochloride tablets-treated patients and 1.0% for placebo-treated patients. The proportion of female patients with prolactin elevations $\geq 5x$ ULN was 1.3% for lurasidone hydrochloride tablets-treated patients and 0% for placebo-treated female patients. The proportion of male patients with prolactin elevations $\geq 5x$ ULN was 0% for lurasidone hydrochloride tablets treated patients and 1.6% for placebo-treated male patients.

Bipolar Depression

<u>Adults</u>

Monotherapy

The median change from baseline to endpoint in prolactin levels, in the adult short-term, flexible-dosed, placebo-controlled monotherapy bipolar depression study, was +1.7 ng/mL and +3.5 ng/mL with lurasidone hydrochloride tablets 20 to 60 mg/day and 80 to 120 mg/day, respectively compared to +0.3 ng/mL with placebo-treated patients. The median change from baseline to endpoint for males was +1.5 ng/mL and for females was +3.1 ng/mL. Median changes for prolactin by dose range are shown in Table 16.

		Lurasidone Hydrochloride Tablets			
	Placebo	20 to 60 mg/day	80 to 120 mg/day		
All Patients	+0.3	+1.7	+3.5		
	(n=147)	(n=140)	(n=144)		
Females	0.0	+1.8	+5.3		
	(n=82)	(n=78)	(n=88)		
Males	+0.4	+1.2	+1.9		
	(n=65)	(n=62)	(n=56)		

Table 16: Median Change in Prolactin (ng/mL) from Baseline in the AdultMonotherapy Bipolar Depression Study

Patients were randomized to flexibly dosed lurasidone hydrochloride tablets 20 to 60 mg/day; lurasidone hydrochloride tablets 80 to 120 mg/day, or placebo

The proportion of patients with prolactin elevations $\geq 5x$ upper limit of normal (ULN) was 0.4% for lurasidone hydrochloride tablets-treated patients and 0.0% for placebo-treated patients. The proportion of female patients with prolactin elevations $\geq 5x$ ULN was 0.6% for lurasidone hydrochloride tablets-treated patients and 0% for placebo-treated female patients. The proportion of male patients with prolactin elevations $\geq 5x$ ULN was 0.6% for placebo-treated female patients. The proportion of male patients with prolactin elevations $\geq 5x$ ULN was 0% and 0% for placebo-treated male patients.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who were treated with lurasidone hydrochloride tablets as monotherapy in the short-term and continued in the longer-term study, had a median change in prolactin of -1.15 ng/mL at week 24 (n=130).

Adjunctive Therapy with Lithium or Valproate

The median change from baseline to endpoint in prolactin levels, in the adult short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies was +2.8 ng/mL with lurasidone hydrochloride tablets 20 to 120 mg/day compared to 0.0 ng/mL with placebo-treated patients. The median change from baseline to endpoint for males was +2.4 ng/mL and for females was +3.2 ng/mL. Median changes for prolactin across the dose range are shown in Table 17.

		Lurasidone Hydrochloride Tablets
	Placebo	20 to 120 mg/day
All Patients	0.0	+2.8
	(n=301)	(n=321)
Females	+0.4	+3.2
	(n=156)	(n=162)

Table 17: Median Change in Prolactin (ng/mL) from Baseline in the AdultAdjunctive Therapy Bipolar Depression Studies

Males	-0.1	+2.4
_	(n=145)	(n=159)

Patients were randomized to flexibly dosed lurasidone hydrochloride tablets 20 to 120 mg/day or placebo as adjunctive therapy with lithium or valproate.

The proportion of patients with prolactin elevations $\geq 5x$ upper limit of normal (ULN) was 0.0% for lurasidone hydrochloride tablets-treated patients and 0.0% for placebo-treated patients. The proportion of female patients with prolactin elevations $\geq 5x$ ULN was 0% for lurasidone hydrochloride tablets-treated patients and 0% for placebo-treated female patients. The proportion of male patients with prolactin elevations $\geq 5x$ ULN was 0% for placebo-treated female patients. The proportion of male patients with prolactin elevations $\geq 5x$ ULN was 0% and 0% for placebo-treated male patients.

In the uncontrolled, open-label, longer-term bipolar depression study, patients who were treated with lurasidone hydrochloride tablets, as adjunctive therapy with either lithium or valproate, in the short-term and continued in the longer-term study, had a median change in prolactin of -2.9 ng/mL at week 24 (n=88).

Pediatric Patients (10 to 17 years)

In the 6-week, placebo-controlled bipolar depression study with pediatric patients 10 to 17 years, the median change from baseline to endpoint in prolactin levels for lurasidone hydrochloride tablets-treated patients was +1.10 ng/mL and was +0.50 ng/mL for placebo-treated patients. For lurasidone hydrochloride tablets-treated patients, the median change from baseline to endpoint for males was +0.85 ng/mL and for females was +2.50 ng/mL. Median changes for prolactin are shown in Table 18.

		Lurasidone Hydrochloride Tablets
	Placebo	20 to 80 mg/day
All Patients	+0.50	+1.10
	(n=157)	(n=165)
Females	+0.55	+2.50
	(n=78)	(n=83)
Males	+0.50	+0.85
	(n=79)	(n=82)

Table 18: Median Change in Prolactin (ng/mL) from Baseline in the Bipolar Depression Study in Pediatric Patients (10 to 17 years)

The proportion of patients with prolactin elevations $\geq 5x$ ULN was 0% for lurasidone hydrochloride tablets-treated patients and 0.6% for placebo-treated patients. The proportion of female patients with prolactin elevations $\geq 5x$ ULN was 0% for lurasidone hydrochloride tablets-treated patients and 1.3% for placebo-treated female patients. No male patients in the placebo or lurasidone hydrochloride tablets treatment groups had prolactin elevations $\geq 5x$ ULN.

Pediatric Patients (6 to 17 years)

In a 104-week, open-label study of pediatric patients with schizophrenia, bipolar depression, or autistic disorder, the median changes from baseline to endpoint in serum prolactin levels were -0.20 ng/mL (all patients), -0.30 ng/mL (females), and -0.05 ng/mL (males). The proportions of patients with a markedly high prolactin level (\geq 5 times the upper limit of normal) at any time during open-label treatment were 2% (all patients), 3% (females), and 1% (males).

Adverse events among females in this trial that are potentially prolactin-related include galactorrhea (0.6%). Among male patients in this study, decreased libido was reported in one patient (0.2%) and there were no reports of impotence, gynecomastia, or

galactorrhea.

5.8 Leukopenia, Neutropenia and Agranulocytosis

Leukopenia/neutropenia has been reported during treatment with antipsychotic agents. Agranulocytosis (including fatal cases) has been reported with other agents in the class.

Possible risk factors for leukopenia/neutropenia include pre-existing low white blood cell count (WBC) and history of drug-induced leukopenia/neutropenia. Patients with a pre-existing low WBC or a history of drug-induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and lurasidone hydrochloride tablets should be discontinued at the first sign of decline in WBC, in the absence of other causative factors.

Patients with neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count < 1,000/mm³) should discontinue lurasidone hydrochloride tablets and have their WBC followed until recovery.

5.9 Orthostatic Hypotension and Syncope

Lurasidone may cause orthostatic hypotension and syncope, perhaps due to its α 1adrenergic receptor antagonism. Associated adverse reactions can include dizziness, lightheadedness, tachycardia, and bradycardia. Generally, these risks are greatest at the beginning of treatment and during dose escalation. Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease, as well as patients who are antipsychotic-naïve. In such patients, consider using a lower starting dose and slower titration, and monitor orthostatic vital signs.

Orthostatic hypotension, as assessed by vital sign measurement, was defined by the following vital sign changes: ≥ 20 mm Hg decrease in systolic blood pressure and ≥ 10 bpm increase in pulse from sitting to standing or supine to standing position.

Schizophrenia

<u>Adults</u>

The incidence of orthostatic hypotension and syncope reported as adverse events from short- term, placebo-controlled schizophrenia studies was (lurasidone hydrochloride tablets incidence, placebo incidence): orthostatic hypotension [0.3% (5/1,508), 0.1% (1/708)] and syncope [0.1% (2/1,508), 0% (0/708)].

In short-term schizophrenia clinical studies, orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 0.8% with lurasidone hydrochloride tablets 40 mg, 2.1% with lurasidone hydrochloride tablets 80 mg, 1.7% with lurasidone hydrochloride tablets 120 mg and 0.8% with lurasidone hydrochloride tablets 160 mg compared to 0.7% with placebo.

<u>Adolescents</u>

The incidence of orthostatic hypotension reported as adverse events from the shortterm, placebo-controlled adolescent schizophrenia study was 0.5% (1/214) in lurasidone hydrochloride tablets-treated patients and 0% (0/112) in placebo-treated patients. No syncope event was reported.

Orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 0% with lurasidone hydrochloride tablets 40 mg and 2.9% with lurasidone hydrochloride tablets 80 mg, compared to 1.8% with placebo.

Bipolar Depression

<u>Adults</u>

Monotherapy

In the adult short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, there were no reported adverse events of orthostatic hypotension and syncope.

Orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 0.6% with lurasidone hydrochloride tablets 20 to 60 mg and 0.6% with lurasidone hydrochloride tablets 80 to 120 mg compared to 0% with placebo.

Adjunctive Therapy with Lithium or Valproate

In the adult short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression therapy studies, there were no reported adverse events of orthostatic hypotension and syncope. Orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 1.1% with lurasidone hydrochloride tablets 20 to 120 mg compared to 0.9% with placebo.

Pediatric Patients (10 to 17 years)

In the 6-week, placebo-controlled bipolar depression study in pediatric patients 10 to 17 years, there were no reported adverse events of orthostatic hypotension or syncope.

Orthostatic hypotension, as assessed by vital signs, occurred with a frequency of 1.1% with lurasidone hydrochloride tablets 20 to 80 mg/day, compared to 0.6% with placebo.

5.10 Falls

Lurasidone hydrochloride tablets may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other injuries. For patients with diseases, conditions, or medications that could exacerbate these effects, complete fall risk assessments when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy.

5.11 Seizures

As with other antipsychotic drugs, lurasidone should be used cautiously in patients with a history of seizures or with conditions that lower the seizure threshold, e.g., Alzheimer's dementia. Conditions that lower the seizure threshold may be more prevalent in patients 65 years or older.

Schizophrenia

In adult short-term, placebo-controlled schizophrenia studies, seizures/convulsions occurred in 0.1% (2/1,508) of patients treated with lurasidone hydrochloride tablets compared to 0.1% (1/708) placebo-treated patients.

Bipolar Depression

Monotherapy

In the adult and pediatric 6-week, flexible-dose, placebo-controlled monotherapy bipolar depression studies, no patients experienced seizures/convulsions.

Adjunctive Therapy with Lithium or Valproate

In the adult short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies, no patient experienced seizures/convulsions.

5.12 Potential for Cognitive and Motor Impairment

Lurasidone, like other antipsychotics, has the potential to impair judgment, thinking or motor skills. Caution patients about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with lurasidone hydrochloride tablets does not affect them adversely.

In clinical studies with lurasidone, somnolence included: hypersomnia, hypersomnolence, sedation and somnolence.

Schizophrenia

<u>Adults</u>

In short-term, placebo-controlled schizophrenia studies, somnolence was reported by 17.0% (256/1,508) of patients treated with lurasidone hydrochloride tablets (15.5% lurasidone hydrochloride tablets 20 mg, 15.6% lurasidone hydrochloride tablets 40 mg, 15.2% lurasidone hydrochloride tablets 80 mg, 26.5% lurasidone hydrochloride tablets 120 mg and 8.3% lurasidone hydrochloride tablets 160 mg/day) compared to 7.1% (50/708) of placebo patients.

Adolescents

In the short-term, placebo-controlled adolescent schizophrenia study, somnolence was reported by 14.5% (31/214) of patients treated with lurasidone hydrochloride tablets (15.5% lurasidone hydrochloride tablets 40 mg and 13.5% lurasidone hydrochloride tablets 80 mg/day) compared to 7.1% (8/112) of placebo patients.

Bipolar Depression Adults

<u>Monotherapy</u>

In the adult short-term, flexible-dosed, placebo-controlled monotherapy bipolar depression study, somnolence was reported by 7.3% (12/164) and 13.8% (23/167) with lurasidone hydrochloride tablets 20 to 60 mg and 80 to 120 mg, respectively compared to 6.5% (11/168) of placebo patients.

Adjunctive Therapy with Lithium or Valproate

In the adult short-term, flexible-dosed, placebo-controlled adjunctive therapy bipolar depression studies, somnolence was reported by 11.4% (41/360) of patients treated with lurasidone hydrochloride tablets 20 to 120 mg compared to 5.1% (17/334) of placebo patients.

Pediatric Patients (10 to 17 years)

In the 6-week, placebo-controlled bipolar depression study in pediatric patients 10 to 17 years, somnolence was reported by 11.4% (20/175) of patients treated with lurasidone hydrochloride tablets 20 to 80 mg/day compared to 5.8% (10/172) of placebo treated patients.

5.13 Body Temperature Dysregulation

Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Appropriate care is advised when prescribing lurasidone hydrochloride tablets for patients who will be experiencing conditions that may contribute to an elevation in core body temperature, e.g., exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration.

5.14 Activation of Mania/Hypomania

Antidepressant treatment can increase the risk of developing a manic or hypomanic episode, particularly in patients with bipolar disorder. Monitor patients for the emergence of such episodes.

In the adult bipolar depression monotherapy and adjunctive therapy (with lithium or valproate) studies, less than 1% of subjects in the lurasidone hydrochloride tablets and placebo groups developed manic or hypomanic episodes.

5.15 Dysphagia

Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Aspiration pneumonia is a common cause of morbidity and mortality in elderly patients, in particular those with advanced Alzheimer's dementia. Lurasidone and other antipsychotic drugs should be used cautiously in patients at risk for aspiration pneumonia.

5.16 Neurological Adverse Reactions in Patients with Parkinson's Disease or Dementia with Lewy Bodies

Patients with Parkinson's Disease or Dementia with Lewy Bodies are reported to have an increased sensitivity to antipsychotic medication. Manifestations of this increased sensitivity include confusion, obtundation, postural instability with frequent falls, extrapyramidal symptoms, and clinical features consistent with the neuroleptic malignant syndrome.

6 ADVERSE REACTIONS

The following adverse reactions are discussed in more detail in other sections of the labeling:

- Increased Mortality in Elderly Patients with Dementia-Related Psychosis [see Boxed Warning and Warnings and Precautions (5.1)]
- Suicidal Thoughts and Behaviors [see Boxed Warning and Warnings and Precautions (5.2)]
- Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-related Psychosis [see Warnings and Precautions (5.3)]
- Neuroleptic Malignant Syndrome [see Warnings and Precautions (5.4)]
- Tardive Dyskinesia [see Warnings and Precautions (5.5)]
- Metabolic Changes [see Warnings and Precautions (5.6)]
- Hyperprolactinemia [see Warnings and Precautions (5.7)]
- Leukopenia, Neutropenia, and Agranulocytosis [see Warnings and Precautions (5.8)]
- Orthostatic Hypotension and Syncope [see Warnings and Precautions (5.9)]
- Falls [see Warnings and Precautions (5.10)]
- Seizures [see Warnings and Precautions (5.11)]
- Potential for Cognitive and Motor Impairment [see Warnings and Precautions (5.12)]
- Body Temperature Dysregulation [see Warnings and Precautions (5.13)]
- Activation of Mania/Hypomania [see Warnings and Precautions (5.14)]
- Dysphagia [see Warnings and Precautions (5.15)]
- Neurological Adverse Reactions in Patients with Parkinson's Disease or Dementia with Lewy Bodies [see Warnings and Precautions (5.16)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Adults

The information below is derived from an integrated clinical study database for lurasidone hydrochloride tablets consisting of 3,799 adult patients exposed to one or more doses of lurasidone hydrochloride tablets for the treatment of schizophrenia, and bipolar depression in placebo-controlled studies. This experience corresponds with a total experience of 1,250.9 patient-years. A total of 1,106 lurasidone hydrochloride tablets-treated patients had at least 24 weeks and 371 lurasidone hydrochloride tablets-treated patients had at least 52 weeks of exposure.

Adverse events during exposure to study treatment were obtained by general inquiry and voluntarily reported adverse experiences, as well as results from physical examinations, vital signs, ECGs, weights and laboratory investigations. Adverse experiences were recorded by clinical investigators using their own terminology. In order to provide a meaningful estimate of the proportion of individuals experiencing adverse events, events were grouped in standardized categories using MedDRA terminology.

Schizophrenia

The following findings are based on the short-term, placebo-controlled premarketing adult studies for schizophrenia in which lurasidone hydrochloride tablets was administered at daily doses ranging from 20 to 160 mg (n=1,508).

<u>Commonly Observed Adverse Reactions</u>: The most common adverse reactions (incidence \geq 5% and at least twice the rate of placebo) in patients treated with lurasidone hydrochloride tablets were somnolence, akathisia, extrapyramidal symptoms, and nausea.

<u>Adverse Reactions Associated with Discontinuation of Treatment</u>: A total of 9.5% (143/1,508) lurasidone hydrochloride tablets-treated patients and 9.3% (66/708) of placebo-treated patients discontinued due to adverse reactions. There were no adverse reactions associated with discontinuation in subjects treated with lurasidone hydrochloride tablets that were at least 2% and at least twice the placebo rate.

<u>Adverse Reactions Occurring at an Incidence of 2% or More in Lurasidone Hydrochloride</u> <u>Tablets-Treated Patients:</u> Adverse reactions associated with the use of lurasidone hydrochloride tablets (incidence of 2% or greater, rounded to the nearest percent and lurasidone hydrochloride tablets incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in patients with schizophrenia) are shown in Table 19.

		Perce	entage o	f Patient	s Report	ting React	tion
			Lurasido	ne Hydro	chloride	Tablets	
Body System or Organ Class		mg/day (N=71)	(N=487))(N=538)	(N=291)		All Lurasidone Hydrochloride
		(%)	(%)	(%)	(%)	(%)	Tablets (N=1,508) (%)
Gastrointestinal Disorders							
Nausea	5	11	10	9	13	7	10
Vomiting	6	7	6	9	9	7	8
Dyspepsia	5	11	6	5	8	6	6
Salivary	<1	1	1	2	4	2	2

Table 19:Adverse Reactions in 2% or More of Lurasidone Hydrochloride Tablets-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in Adult Short-term Schizophrenia Studies

Hypersecretion Musculoskeletal and Connective Tissue

Disorders Back Pain	2	0	4	3	4	0	3
Nervous System Disorders		-		-		-	-
Somnolence*	7	15	16	15	26	8	17
Akathisia	3	6	11	12	22	7	13
Extrapyramidal	6	6	11	12	22	13	14
Disorder**							
Dizziness	2	6	4	4	5	6	4
Psychiatric							
Disorders							
Insomnia	8	8	10	11	9	7	10
Agitation	4	10	7	3	6	5	5
Anxiety	4	3	6	4	7	3	5
Restlessness	1	1	3	1	3	2	2

Note: Figures rounded to the nearest integer

* Somnolence includes adverse event terms: hypersomnia, hypersomnolence, sedation, and somnolence

** Extrapyramidal symptoms include adverse event terms: bradykinesia, cogwheel rigidity, drooling, dystonia, extrapyramidal disorder, hypokinesia, muscle rigidity, oculogyric crisis, oromandibular dystonia, parkinsonism, psychomotor retardation, tongue spasm, torticollis, tremor, and trismus

Dose-Related Adverse Reactions in the Schizophrenia Studies

Akathisia and extrapyramidal symptoms were dose-related. The frequency of akathisia increased with dose up to 120 mg/day (5.6% for lurasidone hydrochloride tablets 20 mg, 10.7% for lurasidone hydrochloride tablets 40 mg, 12.3% for lurasidone hydrochloride tablets 80 mg, and 22.0% for lurasidone hydrochloride tablets 120 mg). Akathisia was reported by 7.4% (9/121) of patients receiving 160 mg/day. Akathisia occurred in 3.0% of subjects receiving placebo. The frequency of extrapyramidal symptoms increased with dose up to 120 mg/day (5.6% for lurasidone hydrochloride tablets 20 mg, 11.5% for lurasidone hydrochloride tablets 40 mg, 11.9% for lurasidone hydrochloride tablets 80 mg, and 22.0% for lurasidone hydrochloride tablets 120 mg).

Bipolar Depression (Monotherapy)

The following findings are based on the adult short-term, placebo-controlled premarketing study for bipolar depression in which lurasidone hydrochloride tablets were administered at daily doses ranging from 20 to 120 mg (n=331).

<u>Commonly Observed Adverse Reactions</u>: The most common adverse reactions (incidence \geq 5%, in either dose group, and at least twice the rate of placebo) in patients treated with lurasidone hydrochloride tablets were akathisia, extrapyramidal symptoms, somnolence, nausea, vomiting, diarrhea, and anxiety.

<u>Adverse Reactions Associated with Discontinuation of Treatment</u>: A total of 6.0% (20/331) lurasidone hydrochloride tablets-treated patients and 5.4% (9/168) of placebotreated patients discontinued due to adverse reactions. There were no adverse reactions associated with discontinuation in subjects treated with lurasidone hydrochloride tablets that were at least 2% and at least twice the placebo rate.

<u>Adverse Reactions Occurring at an Incidence of 2% or More in Lurasidone Hydrochloride</u> <u>Tablets-Treated Patients:</u> Adverse reactions associated with the use of lurasidone hydrochloride tablets (incidence of 2% or greater, rounded to the nearest percent and lurasidone hydrochloride tablets incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in patients with bipolar depression) are shown in Table 20. Table 20: Adverse Reactions in 2% or More of Lurasidone Hydrochloride Tablets-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in the Adult Short-term Monotherapy Bipolar Depression Study

	Percentage of Patients Reporting Reaction						
Body System or Organ Class Dictionary-derived Term	Placebo (N=168) (%)	Lurasidone Hydrochloride Tablets 20 to 60 mg/day (N=164) (%)	Lurasidone Hydrochlorid Tablets 80 to 120 mg/day (N=167) (%)	All e Lurasidone Hydrochloride Tablets (N=331) (%)			
Gastrointestinal Disorder	`S						
Nausea	8	10	17	14			
Dry Mouth	4	6	4	5			
Vomiting	2	2	6	4			
Diarrhea	2	5	3	4			
Infections and Infestatio	ns						
Nasopharyngitis	1	4	4	4			
Influenza	1	<1	2	2			
Urinary Tract Infection	<1	2	1	2			
Musculoskeletal and Con Disorders	nective Tis	sue					
Back Pain	<1	3	<1	2			
Nervous System Disorde	rs						
Extrapyramidal	2	5	9	7			
Symptoms*							
Akathisia	2	8	11	9			
Somnolence**	7	7	14	11			
Psychiatric Disorders							
Anxiety	1	4	5	4			

Note: Figures rounded to the nearest integer

*Extrapyramidal symptoms include adverse event terms: bradykinesia, cogwheel rigidity, drooling, dystonia, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, oculogyric crisis, oromandibular dystonia, parkinsonism, psychomotor retardation, tongue spasm, torticollis, tremor, and trismus

** Somnolence includes adverse event terms: hypersomnia, hypersomnolence, sedation, and somnolence

Dose-Related Adverse Reactions in the Monotherapy Study:

In the adult short-term, placebo-controlled study (involving lower and higher lurasidone hydrochloride tablets dose ranges) [see Clinical Studies (14.2)] the adverse reactions that occurred with a greater than 5% incidence in the patients treated with lurasidone hydrochloride tablets in any dose group and greater than placebo in both groups were nausea (10.4%, 17.4%), somnolence (7.3%, 13.8%), akathisia (7.9%, 10.8%), and extrapyramidal symptoms (4.9%, 9.0%) for lurasidone hydrochloride tablets 20 to 60 mg/day and lurasidone hydrochloride tablets 80 to 120 mg/day, respectively.

Bipolar Depression

Adjunctive Therapy with Lithium or Valproate

The following findings are based on two adult short-term, placebo-controlled premarketing studies for bipolar depression in which lurasidone hydrochloride tablet was administered at daily doses ranging from 20 to 120 mg as adjunctive therapy with

lithium or valproate (n=360).

<u>Commonly Observed Adverse Reactions</u>: The most common adverse reactions (incidence \geq 5% and at least twice the rate of placebo) in subjects treated with lurasidone hydrochloride tablets were akathisia and somnolence.

<u>Adverse Reactions Associated with Discontinuation of Treatment</u>: A total of 5.8% (21/360) lurasidone hydrochloride tablets-treated patients and 4.8% (16/334) of placebo-treated patients discontinued due to adverse reactions. There were no adverse reactions associated with discontinuation in subjects treated with lurasidone hydrochloride tablets that were at least 2% and at least twice the placebo rate.

<u>Adverse Reactions Occurring at an Incidence of 2% or More in Lurasidone Hydrochloride</u> <u>Tablets-Treated Patients:</u> Adverse reactions associated with the use of lurasidone hydrochloride tablets (incidence of 2% or greater, rounded to the nearest percent and lurasidone hydrochloride tablets incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in patients with bipolar depression) are shown in Table 21.

Table 21: Adverse Reactions in 2% or More of Lurasidone Hydrochloride Tablets-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in the Adult Short-term Adjunctive Therapy Bipolar Depression Studies

	Percentage of Patients Reporting Reaction				
Body System or Organ Class Dictionary-derived Term	Placebo (N=334) (%)	Lurasidone Hydrochloride Tablets 20 to 120 mg/day (N=360) (%)			
Gastrointestinal Disorders					
Nausea	10	14			
Vomiting	1	4			
General Disorders					
Fatigue	1	3			
Infections and Infestations					
Nasopharyngitis	2	4			
Investigations					
Weight Increased	<1	3			
Metabolism and Nutrition Disorde	rs				
Increased Appetite	1	3			
Nervous System Disorders					
Extrapyramidal Symptoms*	9	14			
Somnolence**	5	11			
Akathisia	5	11			
Psychiatric Disorders					
Restlessness	<1	4			

Note: Figures rounded to the nearest integer

*Extrapyramidal symptoms include adverse event terms: bradykinesia, cogwheel rigidity, drooling, dystonia, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, oculogyric crisis, oromandibular dystonia, parkinsonism, psychomotor retardation, tongue spasm, torticollis, tremor, and trismus

** Somnolence includes adverse event terms: hypersomnia, hypersomnolence, sedation, and somnolence

Adolescents

Schizophrenia

The following findings are based on the short-term, placebo-controlled adolescent study for schizophrenia in which lurasidone hydrochloride tablet was administered at daily doses ranging from 40 (N=110) to 80 mg (N=104).

<u>Commonly Observed Adverse Reactions</u>: The most common adverse reactions (incidence \geq 5% and at least twice the rate of placebo) in adolescent patients (13 to 17 years) treated with lurasidone hydrochloride tablets were somnolence, nausea, akathisia, extrapyramidal symptoms (non-akathisia, 40 mg only), vomiting, and rhinorrhea/rhinitis (80 mg only).

<u>Adverse Reactions Associated with Discontinuation of Treatment</u>: The incidence of discontinuation due to adverse reactions between lurasidone hydrochloride tablets- and placebo-treated adolescent patients (13 to 17 years) was 4% and 8%, respectively.

<u>Adverse Reactions Occurring at an Incidence of 2% or More in Lurasidone Hydrochloride</u> <u>Tablets-Treated Patients:</u> Adverse reactions associated with the use of lurasidone hydrochloride tablets (incidence of 2% or greater, rounded to the nearest percent and lurasidone hydrochloride tablets incidence greater than placebo) that occurred during acute therapy (up to 6-weeks in adolescent patients with schizophrenia) are shown in Table 22.

Table 22: Adverse Reactions in 2% or More of Lurasidone Hydrochloride Tablets-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in the Adolescent Short-term Schizophrenia Study

	Percentage of Patients Reporting Reaction						
Body System or Organ Class Dictionary-derived Term	Placebo (N=112)	Lurasidone Lurasido Hydrochloride Hydrochlo Tablets Tablets 40 mg/day 80 mg/d (N=110) (N=104		ride All Lurasidone y Hydrochloride			
Gastrointestinal Disorders				(,			
Nausea	3	13	14	14			
Vomiting	2	8	6	8			
Diarrhea	1	3	5	4			
Dry Mouth	0	2	3	2			
Infections and Infestations							
Viral Infection**	6	11	10	10			
Rhinitis ^{***}	2	<1	8	4			
Oropharyngeal pain	0	<1	3	2			
Tachycardia	0	0	3	1			
Nervous System Disorders							
Somnolence*	7	15	13	15			
Akathisia	2	9	9	9			
Dizziness	1	5	5	5			

Note: Figures rounded to the nearest integer

* Somnolence includes adverse event terms: hypersomnia, sedation, and somnolence

** Viral Infection includes adverse event terms: nasopharyngitis, influenza, viral infection, upper respiratory tract infection

*** Rhinitis incudes adverse event terms: rhinitis, allergic rhinitis, rhinorrhea, and nasal congestion

Pediatric Patients (10 to 17 years)

Bipolar Depression

The following findings are based on the 6-week, placebo-controlled study for bipolar depression in pediatric patients 10 to 17 years in which lurasidone hydrochloride tablet was administered at daily doses ranging from 20 to 80 mg (N=175).

<u>Commonly Observed Adverse Reactions</u>: The most common adverse reactions (incidence \geq 5%, and at least twice the rate of placebo) in pediatric patients (10 to 17 years) treated with lurasidone hydrochloride tablets were nausea, weight increase, and insomnia.

<u>Adverse Reactions Associated with Discontinuation of Treatment</u>: The incidence of discontinuation due to adverse reactions between lurasidone hydrochloride tablets- and placebo-treated pediatric patients 10 to 17 years was 2% and 2%, respectively.

Adverse Reactions Occurring at an Incidence of 2% or More in Lurasidone Hydrochloride <u>Tablets-Treated Patients</u>: Adverse reactions associated with the use of lurasidone hydrochloride tablets (incidence of 2% or greater, rounded to the nearest percent and lurasidone hydrochloride tablets incidence greater than placebo) that occurred during acute therapy (up to 6 weeks in pediatric patients with bipolar depression) are shown in Table 23.

Table 23: Adverse Reactions in 2% or More of Lurasidone Hydrochloride Tablets-Treated Patients and That Occurred at Greater Incidence than in the Placebo-Treated Patients in the 6-Week Bipolar Depression Study in Pediatric Patients (10 to 17 years)

	Percentage of Patients Reporting Reaction			
Body System or Organ Class Dictionary-derived Term	Placebo (N=172)	Lurasidone Hydrochloride Tablets 20 to 80 mg/day (N=175)		
Gastrointestinal Disorders				
Nausea	6	16		
Vomiting	4	6		
Abdominal Pain Upper	2	3		
Diarrhea	2	3		
Abdominal Pain	1	3		
General Disorders And Admini	stration Site Cond	litions		
Fatigue	2	3		
Investigations				
Weight Increased	2	7		
Metabolism and Nutrition Diso	rders			
Decreased Appetite	2	4		
Nervous System Disorders				
Somnolence*	6	11		
Extrapyramidal symptoms**	5	6		
Dizziness	5	6		
Psychiatric Disorders				
Insomnia	2	5		
Abnormal Dreams	2	2		
Respiratory, Thoracic and Med	liastinal Disorders	i		
Oropharyngeal Pain	2	2		
Note: Figures rounded to the nearest i	nteger			

Note: Figures rounded to the nearest integer

*Somnolence includes adverse event terms: hypersomnia, hypersomnolence, sedation, and somnolence

**EPS includes adverse event terms: akathisia, cogwheel rigidity, dyskinesia, dystonia, hyperkinesia, joint stiffness, muscle rigidity, muscle spasms, musculoskeletal stiffness, oculogyric crisis, parkinsonism, tardive dyskinesia, and tremor

Extrapyramidal Symptoms

Schizophrenia

<u>Adults</u>

In the short-term, placebo-controlled schizophrenia studies, for lurasidone hydrochloride tablets -treated patients, the incidence of reported events related to extrapyramidal symptoms (EPS), excluding akathisia and restlessness, was 13.5% and 5.8% for placebo-treated patients. The incidence of akathisia for lurasidone hydrochloride tablets-treated patients was 12.9% and 3.0% for placebo-treated patients. Incidence of EPS by dose is provided in Table 24.

Table 24: Incidence of EPS Compared to Placebo in Adult SchizophreniaStudies

			Hydrod	idone chloride olets		
Adverse Event Term	Placebo (N=708) (%)	20 mg/day (N=71) (%)	40 mg/day (N=487) (%)	80 mg/day (N=538) (%)	120 mg/day (N=291) (%)	160 mg/day (N=121) (%)
All EPS events	9	10	21	23	39	20
All EPS events, excluding Akathisia/Restlessnes	6 s	6	11	12	22	13
Akathisia	3	6	11	12	22	7
Dystonia*	<1	0	4	5	7	2
Parkinsonism**	5	6	9	8	17	11
Restlessness	1	1	3	1	3	2

Note: Figures rounded to the nearest integer

* Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus

** Parkinsonism includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, extrapyramidal disorder, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremor

<u>Adolescents</u>

In the short-term, placebo-controlled, study of schizophrenia in adolescents, the incidence of EPS, excluding events related to akathisia, for lurasidone hydrochloride tablets-treated patients was higher in the 40 mg (10%) and the 80 mg (7.7%) treatment groups vs. placebo (3.6%); and the incidence of akathisia-related events for lurasidone hydrochloride tablets-treated patients was 8.9% vs. 1.8% for placebo-treated patients. Incidence of EPS by dose is provided in Table 25.

Table 25: Incidence of EPS Compared to Placebo in the AdolescentSchizophrenia Study

		Lurasidone Hydrochloride Tablets			
Adverse Event Term	Placebo	40 mg/day	80 mg/day		

	(N=112) (%)	(N=110) (%)	(N=104) (%)
All EPS events	5	14	14
All EPS events, excluding Akathisia/Restlessness	4	7	7
Akathisia	2	9	9
Parkinsonism**	<1	4	0
Dyskinesia	<1	<1	1
Dystonia*	0	<1	1

Note: Figures rounded to the nearest integer

* Dystonia includes adverse event terms: dystonia, trismus, oculogyric crisis, oromandibular dystonia, tongue spasm, and torticollis

** Parkinsonism includes adverse event terms: bradykinesia, drooling, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, parkinsonism, and psychomotor retardation

Bipolar Depression

<u>Adults</u>

Monotherapy

In the adult short-term, placebo-controlled monotherapy bipolar depression study, for lurasidone hydrochloride tablets-treated patients, the incidence of reported events related to EPS, excluding akathisia and restlessness was 6.9% and 2.4% for placebo-treated patients. The incidence of akathisia for lurasidone hydrochloride tablets-treated patients was 9.4% and 2.4% for placebo-treated patients. Incidence of EPS by dose groups is provided in Table 26.

Table 26: Incidence of EPS Compared to Placebo in the Adult MonotherapyBipolar Depression Study

		Lurasidone Hydrochloride Tablets			
Adverse Event Term	Placebo (N=168) (%)	20 to 60 mg/day (N=164) (%)	80 to 120 mg/day (N=167) (%)		
All EPS events	5	12	20		
All EPS events, excluding Akathisia/Restlessness	2	5	9		
Akathisia	2	8	11		
Dystonia*	0	0	2		
Parkinsonism**	2	5	8		
Restlessness	<1	0	3		

Note: Figures rounded to the nearest integer

* Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus

** Parkinsonism includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremor

Adjunctive Therapy with Lithium or Valproate

In the adult short-term, placebo-controlled adjunctive therapy bipolar depression studies, for lurasidone hydrochloride tablets-treated patients, the incidence of EPS, excluding akathisia and restlessness, was 13.9% and 8.7% for placebo. The incidence of akathisia for lurasidone hydrochloride tablets-treated patients was 10.8% and 4.8% for

Adverse Event Term	Placebo (N=334) (%)	Lurasidone Hydrochloride Tablets 20 to 120 mg/day (N=360) (%)
All EPS events	13	24
All EPS events, excluding Akathisia/Restlessness	9	14
Akathisia	5	11
Dystonia*	<1	1
Parkinsonism**	8	13
Restlessness	<1	4

Table 27: Incidence of EPS Compared to Placebo in the Adult AdjunctiveTherapy Bipolar Depression Studies

Note: Figures rounded to the nearest integer

* Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus

** Parkinsonism includes adverse event terms: bradykinesia, cogwheel rigidity, drooling, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, muscle rigidity, parkinsonism, psychomotor retardation, and tremor

In the short-term, placebo-controlled schizophrenia and bipolar depression studies, data was objectively collected on the Simpson Angus Rating Scale (SAS) for extrapyramidal symptoms (EPS), the Barnes Akathisia Scale (BAS) for akathisia and the Abnormal Involuntary Movement Scale (AIMS) for dyskinesias.

Pediatric Patients (10 to 17 years)

In the 6-week, placebo-controlled study of bipolar depression in pediatric patients 10 to 17 years, the incidence of EPS, excluding events related to akathisia, for lurasidone hydrochloride tablets-treated patients was similar in the lurasidone hydrochloride tablets 20 to 80 mg/day (3.4%) treatment group vs. placebo (3.5%); and the incidence of akathisia-related events for lurasidone hydrochloride tablets-treated patients was 2.9% vs. 3.5% for placebo-treated patients. Incidence of EPS by dose is provided in Table 28.

Table 28: Incidence of EPS Compared to Placebo in the Bipolar DepressionStudy in Pediatric Patients (10 to 17 years)

Adverse Event Term	Placebo (N=172) (%)	Lurasidone Hydrochloride Tablets 20 to 80 mg/day (N=175) (%)
All EPS events*	5	6
All EPS events, excluding	4	3
Akathisia/Restlessness		
Akathisia	4	3
Parkinsonism**	<1	<1
Dystonia***	1	<1
Salivary hypersecretion	<1	<1
Psychomotor hyperactivity	0	<1
Tardive Dyskinesia	<1	0

Note: Figures rounded to the nearest integer

- * EPS include adverse event terms: akathisia, cogwheel rigidity, dyskinesia, dystonia, hyperkinesia, joint stiffness, muscle rigidity, muscle spasms, musculoskeletal stiffness, oculogyric crisis, parkinsonism, tardive dyskinesia, and tremor
- ** Parkinsonism includes adverse event terms: bradykinesia, drooling, extrapyramidal disorder, glabellar reflex abnormal, hypokinesia, parkinsonism, and psychomotor retardation
- ***Dystonia includes adverse event terms: dystonia, oculogyric crisis, oromandibular dystonia, tongue spasm, torticollis, and trismus

Schizophrenia

<u>Adults</u>

The mean change from baseline for lurasidone hydrochloride tablets-treated patients for the SAS, BAS and AIMS was comparable to placebo-treated patients, with the exception of the Barnes Akathisia Scale global score (lurasidone hydrochloride tablets, 0.1; placebo, 0.0). The percentage of patients who shifted from normal to abnormal was greater in lurasidone hydrochloride tablets-treated patients and placebo for the BAS (lurasidone hydrochloride tablets, 14.4%; placebo, 7.1%), the SAS (lurasidone hydrochloride tablets, 5.0%; placebo, 2.3%) and the AIMS (lurasidone hydrochloride tablets, 7.4%; placebo, 5.8%).

<u>Adolescents</u>

The mean change from baseline for lurasidone hydrochloride tablets-treated patients with adolescent schizophrenia for the SAS, BAS and AIMS was comparable to placebotreated patients. The percentage of patients who shifted from normal to abnormal was greater in lurasidone hydrochloride tablets-treated patients and placebo for the BAS (lurasidone hydrochloride tablets, 7.0%; placebo, 1.8%), the SAS (lurasidone hydrochloride tablets, 8.3%; placebo, 2.7%) and the AIMS (lurasidone hydrochloride tablets, 2.8%; placebo, 0.9%).

Bipolar Depression

<u>Adults</u>

Monotherapy

The mean change from baseline for lurasidone hydrochloride tablets-treated adult patients for the SAS, BAS and AIMS was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater in lurasidone hydrochloride tablets-treated patients and placebo for the BAS (lurasidone hydrochloride tablets, 8.4%; placebo, 5.6%), the SAS (lurasidone hydrochloride tablets, 3.7%; placebo, 1.9%) and the AIMS (lurasidone hydrochloride tablets, 3.4%; placebo, 1.2%).

Adjunctive Therapy with Lithium or Valproate

The mean change from baseline for lurasidone hydrochloride tablets-treated adult patients for the SAS, BAS and AIMS was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater in lurasidone hydrochloride tablets-treated patients and placebo for the BAS (lurasidone hydrochloride tablets, 8.7%; placebo, 2.1%), the SAS (lurasidone hydrochloride tablets, 2.8%; placebo, 2.1%) and the AIMS (lurasidone hydrochloride tablets, 2.8%; placebo, 0.6%).

Pediatric Patients (10 to 17 years)

The mean change from baseline for lurasidone hydrochloride tablets-treated pediatric patients 10 to 17 years with bipolar depression for the SAS, BAS and AIMS was comparable to placebo-treated patients. The percentage of patients who shifted from normal to abnormal was greater in lurasidone hydrochloride tablets-treated patients and placebo for the BAS (lurasidone hydrochloride tablets, 4.6%; placebo, 2.4%), the SAS (lurasidone hydrochloride tablets, 0.6%; placebo, 0%) and was the same for the AIMS

(lurasidone hydrochloride tablets, 0%; placebo, 0%).

<u>Dystonia</u>

Class Effect: Symptoms of dystonia, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, difficulty breathing, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first-generation antipsychotic drugs. An elevated risk of acute dystonia is observed in males and younger age groups.

Schizophrenia

<u>Adults</u>

In the short-term, placebo-controlled schizophrenia clinical studies, dystonia occurred in 4.2% of lurasidone hydrochloride tablets-treated subjects (0.0% lurasidone hydrochloride tablets 20 mg, 3.5% lurasidone hydrochloride tablets 40 mg, 4.5% lurasidone hydrochloride tablets 80 mg, 6.5% lurasidone hydrochloride tablets 120 mg and 2.5% lurasidone hydrochloride tablets 160 mg) compared to 0.8% of subjects receiving placebo. Seven subjects (0.5%, 7/1,508) discontinued clinical trials due to dystonic events – four were receiving lurasidone hydrochloride tablets 120 mg/day.

<u>Adolescents</u>

In the short-term, placebo-controlled, adolescent schizophrenia study, dystonia occurred in 1% of lurasidone hydrochloride tablets-treated patients (1% lurasidone hydrochloride tablets 40 mg and 1% lurasidone hydrochloride tablets 80 mg) compared to 0% of patients receiving placebo. No patients discontinued the clinical study due to dystonic events.

Bipolar Depression

<u>Adults</u>

Monotherapy

In the adult short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, dystonia occurred in 0.9% of lurasidone hydrochloride tablets-treated subjects (0.0% and 1.8% for lurasidone hydrochloride tablets 20 to 60 mg/day and lurasidone hydrochloride tablets 80 to 120 mg/day, respectively) compared to 0.0% of subjects receiving placebo. No subject discontinued the clinical study due to dystonic events.

Adjunctive Therapy with Lithium or Valproate

In the adult short-term, flexible-dose, placebo-controlled adjunctive therapy bipolar depression studies, dystonia occurred in 1.1% of lurasidone hydrochloride tablets-treated subjects (20 to 120 mg) compared to 0.6% of subjects receiving placebo. No subject discontinued the clinical study due to dystonic events.

Pediatric Patients (10 to 17 years)

In the 6-week, placebo-controlled bipolar depression study in pediatric patients 10 to 17 years, dystonia occurred in 0.6% of lurasidone hydrochloride tablets-treated patients compared to 1.2% of patients receiving placebo. No patients discontinued the clinical study due to dystonic events.

Other Adverse Reactions Observed During the Premarketing Evaluation of Lurasidone Hydrochloride Tablets Following is a list of adverse reactions reported by adult patients treated with lurasidone hydrochloride tablets at multiple doses of \geq 20 mg once daily within the premarketing database of 2,905 patients with schizophrenia. The reactions listed are those that could be of clinical importance, as well as reactions that are plausibly drug-related on pharmacologic or other grounds. Reactions listed in Table 19 or those that appear elsewhere in the lurasidone hydrochloride tablets label are not included.

Reactions are further categorized by organ class and listed in order of decreasing frequency according to the following definitions: those occurring in at least 1/100 patients (frequent) (only those not already listed in the tabulated results from placebocontrolled studies appear in this listing); those occurring in 1/100 to 1/1,000 patients (infrequent); and those occurring in fewer than 1/1,000 patients (rare).

Blood and Lymphatic System Disorders: Infrequent: anemia

Cardiac Disorders: **Frequent:** tachycardia; **Infrequent:** AV block 1st degree, angina pectoris, bradycardia

Ear and Labyrinth Disorders: Infrequent: vertigo

Eye Disorders: Frequent: blurred vision

Gastrointestinal Disorders: **Frequent:** abdominal pain, diarrhea; **Infrequent:** gastritis General Disorders and Administrative Site Conditions: **Rare:** sudden death Investigations: **Frequent:** CPK increased

Metabolism and Nutritional System Disorders: **Frequent:** decreased appetite Musculoskeletal and Connective Tissue Disorders: **Rare:** rhabdomyolysis Nervous System Disorders: **Infrequent:** cerebrovascular accident, dysarthria

Psychiatric Disorders: Infrequent: abnormal dreams, panic attack, sleep disorder

Renal and Urinary Disorders: Infrequent: dysuria; Rare: renal failure

Reproductive System and Breast Disorders: **Infrequent:** amenorrhea, dysmenorrhea; **Rare:** breast enlargement, breast pain, galactorrhea, erectile dysfunction, priapism

Skin and Subcutaneous Tissue Disorders: Frequent: rash, pruritus; Rare: angioedema

Vascular Disorders: Frequent: hypertension

Clinical Laboratory Changes

Schizophrenia

<u>Adults</u>

Serum Creatinine: In short-term, placebo-controlled trials, the mean change from Baseline in serum creatinine was +0.05 mg/dL for lurasidone hydrochloride tabletstreated patients compared to +0.02 mg/dL for placebo-treated patients. A creatinine shift from normal to high occurred in 3.0% (43/1,453) of lurasidone hydrochloride tablets-treated patients and 1.6% (11/681) on placebo. The threshold for high creatinine value varied from >0.79 to >1.3 mg/dL based on the centralized laboratory definition for each study (Table 29).

Table 29:Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point inAdult Schizophrenia Studies

			Lurasidone Hydrochloride	Lurasidone Hydrochloride	Lurasidone Hydrochloride	Lurasidone Hydrochloride
		Tablets 20 mg/day (N=71)	Tablets 40 mg/day (N=487)	Tablets 80 mg/day (N=538)	Tablets 120 mg/day (N=291)	Tablets 160 mg/day (N=121)
Serum	2%	1%	2%	2%	5%	7%

Adolescents

Serum Creatinine: In the short-term, placebo-controlled, adolescent schizophrenia study, the mean change from Baseline in serum creatinine was -0.009 mg/dL for lurasidone hydrochloride tablets-treated patients compared to +0.017 mg/dL for placebo-treated patients. A creatinine shift from normal to high (based on the centralized laboratory definition) occurred in 7.2% (14/194) of lurasidone hydrochloride tablets-treated patients and 2.9% (3/103) on placebo (Table 30).

Table 30: Serum Creatinine Shifts from Normal at Baseline to High at StudyEnd-Point in the Adolescent Schizophrenia Study

Laboratory Parameter	Placebo	Lurasidone	Lurasidone
-		Hydrochloride	Hydrochloride
	(N=103)	Tablets	Tablets
		40 mg/day	80 mg/day
		(N=97)	(N=97)
Serum Creatinine Elevated	2.9%	7.2%	7.2%

Bipolar Depression

<u>Adults</u>

Monotherapy

Serum Creatinine: In the adult short-term, flexible-dose, placebo-controlled monotherapy bipolar depression study, the mean change from Baseline in serum creatinine was +0.01 mg/dL for lurasidone hydrochloride tablets-treated patients compared to -0.02 mg/dL for placebo-treated patients. A creatinine shift from normal to high occurred in 2.8% (9/322) of lurasidone hydrochloride tablets-treated patients and 0.6% (1/162) on placebo (Table 31).

			-
Laboratory Parameter	Placebo (N=168)	Lurasidone Hydrochloride	Lurasidone Hydrochloride
		Tablets 20 to 60 mg/day (N=164)	Tablets 80 to 120 mg/day (N=167)
Serum Creatinine Elevated	<1%	2%	4%

Table 31:Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in the Adult Monotherapy Bipolar Depression Study

Adjunctive Therapy with Lithium or Valproate

Serum Creatinine: In adult short-term, placebo-controlled premarketing adjunctive studies for bipolar depression, the mean change from Baseline in serum creatinine was +0.04 mg/dL for lurasidone hydrochloride tablets-treated patients compared to -0.01 mg/dL for placebo-treated patients. A creatinine shift from normal to high occurred in 4.3% (15/360) of lurasidone hydrochloride tablets-treated patients and 1.6% (5/334) on placebo (Table 32).

Table 32: Serum Creatinine Shifts from Normal at Baseline to High at StudyEnd-Point in the Adult Adjunctive Therapy Bipolar Depression Studies

Laboratory Parameter	Placebo (N=334)	Lurasidone Hydrochloride Tablets 20 to 120 mg/day (N=360)
Serum Creatinine Elevated	2%	4%

Pediatric Patients (10 to 17 years)

Serum Creatinine: In the 6-week, placebo-controlled bipolar depression study in pediatric patients 10 to 17 years, the mean change from Baseline in serum creatinine was +0.021 mg/dL for lurasidone hydrochloride tablets-treated patients compared to +0.009 mg/dL for placebo-treated patients. A creatinine shift from normal to high (based on the centralized laboratory definition) occurred in 6.7% (11/163) of lurasidone hydrochloride tablets-treated patients and 4.5% (7/155) on placebo (Table 33).

Table 33: Serum Creatinine Shifts from Normal at Baseline to High at Study End-Point in the Bipolar Depression Study in Pediatric Patients (10 to 17 vears)

Laboratory Parameter	Placebo (N=155)	Lurasidone Hydrochloride Tablets 20 to 80 mg/day (N=163)
Serum Creatinine Elevated	4.5%	6.7%

Pediatric Patients (6 to 17 years)

In a 104-week, open-label study in pediatric patients with schizophrenia, bipolar depression, or autistic disorder, the mean change from baseline to Week 104 in serum creatinine was +0.07 mg/dL. In patients with a normal serum creatinine at baseline, 6% experienced a shift to high at endpoint.

6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of lurasidone hydrochloride tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hypersensitivity Reactions: Urticaria, throat swelling, tongue swelling, dyspnea, and rash.

Metabolism and Nutrition Disorders: Hyponatremia

7 DRUG INTERACTIONS

7.1 Drugs Having Clinically Important Interactions with Lurasidone

Table 34: Clinically Important Drug Interactions with Lurasidone

Strong CYP3A4 Inhibitors				
Clinical Impact:	Concomitant use of lurasidone hydrochloride tablets with			
	strong CYP3A4 inhibitors increased the exposure of			

	lurasidone compared to the use of lurasidone hydrochloride tablets alone [<i>see Clinical Pharmacology (12.3)</i>].
Intervention:	Lurasidone hydrochloride tablets should not be used concomitantly with strong CYP3A4 inhibitors [see Contraindications (4)].
Examples:	Ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil
Moderate CYP3A4	Inhibitors
Clinical Impact:	Concomitant use of lurasidone hydrochloride tablets with moderate CYP3A4 inhibitors increased the exposure of lurasidone compared to the use of lurasidone hydrochloride tablets alone [<i>see Clinical Pharmacology (12.3)</i>].
Intervention:	Lurasidone hydrochloride tablets dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4 [<i>s e e Dosage and</i> <i>Administration (2.6)</i>].
Examples:	Diltiazem, atazanavir, erythromycin, fluconazole, verapamil
Strong CYP3A4 Inc	ducers
Clinical Impact:	Concomitant use of lurasidone hydrochloride tablets with strong CYP3A4 inducers decreased the exposure of lurasidone compared to the use of lurasidone hydrochloride tablets alone [<i>see Clinical Pharmacology</i> (12.3)].
Intervention:	Lurasidone hydrochloride tablets should not be used concomitantly with strong CYP3A4 inducers [<i>see Contraindications (4)</i>].
Examples:	Rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine
Moderate CYP3A4	
Clinical Impact:	Concomitant use of lurasidone hydrochloride tablets with moderate CYP3A4 inducers decreased the exposure of lurasidone compared to the use of lurasidone hydrochloride tablets alone [<i>see Clinical Pharmacology (12.3)</i>].
Intervention:	Lurasidone hydrochloride tablets dose should be increased when used concomitantly with moderate inducers of CYP3A4 [see Dosage and Administration (2.6)].
Examples:	Bosentan, efavirenz, etravirine, modafinil, nafcillin

7.2 Drugs Having No Clinically Important Interactions with Lurasidone

Based on pharmacokinetic studies, no dosage adjustment of lurasidone hydrochloride is required when administered concomitantly with lithium, valproate, or substrates of P-gp or CYP3A4 [see Clinical Pharmacology (12.3)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lurasidone hydrochloride tablets during pregnancy. For more information, contact the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/.

<u>Risk Summary</u>

Neonates exposed to antipsychotic drugs during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery [see Clinical Considerations]. There are no studies of lurasidone hydrochloride tablets use in pregnant women. The limited available data are not sufficient to inform a drug-associated risk of birth defects or miscarriage. In animal reproduction studies, no teratogenic effects were seen in pregnant rats and rabbits given lurasidone during the period of organogenesis at doses approximately 1.5- and 6-times, the maximum recommended human dose (MRHD) of 160 mg/day, respectively based on mg/m² body surface area [see Data].

The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Clinical Considerations

Fetal/Neonatal Adverse Reactions

Extrapyramidal and/or withdrawal symptoms, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder have been reported in neonates who were exposed to antipsychotic drugs during the third trimester of pregnancy. These symptoms have varied in severity. Some neonates recovered within hours or days without specific treatment; others required prolonged hospitalization. Monitor neonates for extrapyramidal and/or withdrawal symptoms and manage symptoms appropriately.

<u>Data</u>

Animal Data

Pregnant rats were treated with oral lurasidone at doses of 3, 10, and 25 mg/kg/day during the period of organogenesis. These doses are 0.2, 0.6, and 1.5 times the MRHD of 160 mg/day based on mg/m² body surface area. No teratogenic or embryo-fetal effects were observed up to 1.5 times the MRHD of 160 mg/day, based on mg/m².

Pregnant rabbits were treated with oral lurasidone at doses of 2, 10, and 50 mg/kg/day during the period of organogenesis. These doses are 0.2, 1.2 and 6 times the MRHD of 160 mg/day based on mg/m². No teratogenic or embryo-fetal effects were observed up to 6 times the MRHD of 160 mg/day based on mg/m².

Pregnant rats were treated with oral lurasidone at doses of 0.4, 2, and 10 mg/kg/day during the periods of organogenesis and lactation. These doses are 0.02, 0.1 and 0.6 times the MRHD of 160 mg/day based on mg/m². No pre- and postnatal developmental effects were observed up to 0.6 times the MRHD of 160 mg/day, based on mg/m².

8.2 Lactation

<u>Risk Summary</u>

Lactation studies have not been conducted to assess the presence of lurasidone in human milk, the effects on the breastfed infant, or the effects on milk production. Lurasidone is present in rat milk. The development and health benefits of breastfeeding should be considered along with the mother's clinical need for lurasidone hydrochloride tablets and any potential adverse effects on the breastfed infant from lurasidone hydrochloride tablets or from the underlying maternal condition.

8.4 Pediatric Use

Schizophrenia

The safety and effectiveness of lurasidone hydrochloride tablets 40-mg/day and 80-mg/day for the treatment of schizophrenia in adolescents (13 to 17 years) was established in a 6-week, placebo-controlled clinical study in 326 adolescent patients [see Dosage and Administration (2.1), Adverse Reactions (6.1), and Clinical Studies (14.1)].

The safety and effectiveness of lurasidone hydrochloride tablets have not been established in pediatric patients less than 13 years of age with schizophrenia.

Bipolar Depression

The safety and effectiveness of lurasidone hydrochloride tablets 20 to 80 mg/day for the treatment of bipolar depression in pediatric patients (10 to 17 years) was established in a 6-week, placebo-controlled clinical study in 347 pediatric patients [see Dosage and Administration (2.2), Adverse Reactions (6.1), and Clinical Studies (14.2)].

The safety and effectiveness of lurasidone hydrochloride tablets have not been established in pediatric patients less than 10 years of age with bipolar depression.

Irritability Associated with Autistic Disorder

The effectiveness of lurasidone hydrochloride tablets in pediatric patients for the treatment of irritability associated with autistic disorder has not been established.

Efficacy was not demonstrated in a 6-week study evaluating lurasidone hydrochloride tablets 20 mg/day and 60 mg/day for the treatment of pediatric patients 6 to 17 years of age with irritability associated with autistic disorder diagnosed by Diagnostic and Statistical Manual of Mental Disorders, 4th Ed., Text Revision [DSM-IV-TR] criteria. The primary objective of the study as measured by improvement from Baseline in the irritability subscale of the Aberrant Behavior Checklist (ABC) at Endpoint (Week 6) was not met. A total of 149 patients were randomized to lurasidone hydrochloride tablets or placebo. Vomiting occurred at a higher rate than reported in other lurasidone hydrochloride tablets studies (4/49 or 8% for 20mg, 14/51 or 27% for 60mg, and 2/49 or 4% for placebo), particularly in children ages 6 to 12 (13 out of 18 patients on lurasidone hydrochloride tablets with vomiting).

In a long-term, open-label study that enrolled pediatric patients (age 6 to 17 years) with schizophrenia, bipolar depression, or autistic disorder from three short-term, placebocontrolled trials, 54% (378/701) received lurasidone for 104 weeks. There was one adverse event in this trial that was considered possibly drug-related and has not been reported in adults receiving lurasidone: a 10 year old male experienced a prolonged, painful erection, consistent with priapism, that led to treatment discontinuation.

In this trial, the mean increase in height from open-label baseline to Week 104 was 4.94 cm. To adjust for normal growth, z-scores were derived (measured in standard deviations [SD]), which normalize for the natural growth of children and adolescents by comparisons to age- and sex-matched population standards. A z-score change <0.5 SD is considered not clinically significant. In this trial, the mean change in height z-score from open-label baseline to Week 104 was +0.05 SD, indicating minimal deviation from the normal growth curve.

Juvenile animal studies

Adverse effects were seen on growth, physical and neurobehavioral development at doses as low as 0.2 times the MRHD based on mg/m². Lurasidone was orally administered to rats from postnatal days 21 through 91 (this period corresponds to childhood, adolescence, and young adulthood in humans) at doses of 3, 30, and 150 (males) or 300 (females) mg/kg/day which are 0.2 to 10 times (males) and 20 times (females) the maximum recommended adult human dose (MRHD) of 160 mg/day based

on mg/m². The adverse effects included dose-dependent decreases in femoral length, bone mineral content, body and brain weights at 2 times the MRHD in both sexes, and motor hyperactivity at 0.2 and 2 times the MRHD in both sexes based on mg/m². In females, there was a delay in attainment of sexual maturity at 2 times the MRHD, associated with decreased serum estradiol. Mortality occurred in both sexes during early post- weaning period and some of the male weanlings died after only 4 treatments at doses as low as 2 times the MRHD based on mg/m². Histopathological findings included increased colloid in the thyroids and inflammation of the prostate in males at 10 times MRHD based on mg/m² and mammary gland hyperplasia, increased vaginal mucification, and increased ovarian atretic follicles at doses as low as 0.2 times the MRHD based on mg/m². Some of these findings were attributed to transiently elevated serum prolactin which was seen in both sexes at all doses. However, there were no changes at any dose level in reproductive parameters (fertility, conception indices, spermatogenesis, estrous cycle, gestation length, parturition, number of pups born). The no effect dose for neurobehavioral changes in males is 0.2 times the MRHD based on mg/m^2 and could not be determined in females. The no effect dose for growth and physical development in both sexes is 0.2 times the MRHD based on mg/m^2 .

8.5 Geriatric Use

Clinical studies with lurasidone hydrochloride tablets did not include sufficient numbers of patients aged 65 and older to determine whether or not they respond differently from younger patients. In elderly patients with psychosis (65 to 85), lurasidone hydrochloride tablets concentrations (20 mg/day) were similar to those in young subjects. It is unknown whether dose adjustment is necessary on the basis of age alone.

Elderly patients with dementia-related psychosis treated with lurasidone hydrochloride tablets are at an increased risk of death compared to placebo. Lurasidone hydrochloride tablets are not approved for the treatment of patients with dementia-related psychosis *[see Boxed Warning, Warnings and Precautions (5.1, 5.3)]*.

8.6 Renal Impairment

Reduce the maximum recommended dosage in patients with moderate or severe renal impairment (CLcr<50 mL/minute). Patients with impaired renal function (CLcr<50 mL/minute) had higher exposure to lurasidone than patients with normal renal function [see Clinical Pharmacology (12.3)]. Greater exposure may increase the risk of lurasidone hydrochloride tablets-associated adverse reactions [see Dosage and Administration (2.4)]

8.7 Hepatic Impairment

Reduce the maximum recommended dosage in patients with moderate to severe hepatic impairment (Child-Pugh score \geq 7). Patients with moderate to severe hepatic impairment (Child-Pugh score \geq 7) generally had higher exposure to lurasidone than patients with normal hepatic function [see Clinical Pharmacology (12.3)]. Greater exposure may increase the risk of lurasidone hydrochloride tablets-associated adverse reactions [see Dosage and Administration (2.5)].

8.8 Other Specific Populations

No dosage adjustment for lurasidone hydrochloride tablets is required on the basis of a patient's sex, race, or smoking status [see Clinical Pharmacology (12.3)].

9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

Lurasidone hydrochloride is not a controlled substance.

9.2 Abuse

Lurasidone hydrochloride tablets have not been systematically studied in humans for its potential for abuse or physical dependence or its ability to induce tolerance. While clinical studies with lurasidone hydrochloride tablets did not reveal any tendency for drugseeking behavior, these observations were not systematic and it is not possible to predict the extent to which a CNS-active drug will be misused, diverted and/or abused once it is marketed. Patients should be evaluated carefully for a history of drug abuse, and such patients should be observed carefully for signs of lurasidone hydrochloride tablets misuse or abuse (e.g., development of tolerance, drug-seeking behavior, increases in dose).

10 OVERDOSAGE

10.1 Human Experience

In premarketing clinical studies, accidental or intentional overdosage of lurasidone hydrochloride tablets was identified in one patient who ingested an estimated 560 mg of lurasidone hydrochloride tablets. This patient recovered without sequelae. This patient resumed lurasidone hydrochloride tablets treatment for an additional two months.

10.2 Management of Overdosage

No specific antidotes for lurasidone are known. In managing overdose, provide supportive care, including close medical supervision and monitoring, and consider the possibility of multiple drug involvement. If an overdose occurs, consult a Certified Poison Control Center (1-800-222-1222 or www.poison.org).

Cardiovascular monitoring should commence immediately, including continuous electrocardiographic monitoring for possible arrhythmias. If antiarrhythmic therapy is administered, disopyramide, procainamide, and quinidine carry a theoretical hazard of additive QT-prolonging effects when administered in patients with an acute overdose of lurasidone. Similarly, the alpha-blocking properties of bretylium might be additive to those of lurasidone, resulting in problematic hypotension.

Hypotension and circulatory collapse should be treated with appropriate measures. Epinephrine and dopamine should not be used, or other sympathomimetics with betaagonist activity, since beta stimulation may worsen hypotension in the setting of lurasidone-induced alpha blockade. In case of severe extrapyramidal symptoms, anticholinergic medication should be administered.

Gastric lavage (after intubation if patient is unconscious) and administration of activated charcoal together with a laxative should be considered.

The possibility of obtundation, seizures, or dystonic reaction of the head and neck following overdose may create a risk of aspiration with induced emesis.

11 DESCRIPTION

Lurasidone hydrochloride is an atypical antipsychotic belonging to the chemical class of benzisothiazol derivatives.

Its chemical name is $(3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl] cyclohexylmethyl}hexahydro-4,7-methano-2$ *H*-isoindole-1,3-dione hydrochloride. Its molecular formula is C₂₈H₃₆N₄O₂S·HCl and its molecular weight is 529.14.

The chemical structure is:

Lurasidone hydrochloride is a white to off-white powder. It is very slightly soluble in water, practically insoluble or insoluble in 0.1 N HCl, slightly soluble in ethanol, sparingly soluble in methanol, practically insoluble or insoluble in toluene and very slightly soluble in acetone.

Lurasidone hydrochloride tablets are intended for oral administration only. Each tablet contains 20 mg, 40 mg, 60 mg, 80 mg or 120 mg of lurasidone hydrochloride.

Inactive ingredients are: croscarmellose sodium, hypromellose, magnesium stearate, mannitol, polyethylene glycol, pregelatinized starch and titanium dioxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The mechanism of action of lurasidone in the treatment of schizophrenia and bipolar depression is unclear. However, its efficacy in schizophrenia and bipolar depression could be mediated through a combination of central dopamine D2 and serotonin Type 2 ($5HT_{2A}$) receptor antagonism.

12.2 Pharmacodynamics

Lurasidone is an antagonist with high affinity binding at the dopamine D2 receptors (Ki of 1 nM) and the serotonin 5-HT_{2A} (Ki of 0.5 nM) and 5-HT₇ (Ki of 0.5 nM) receptors. It also binds with moderate affinity to the human α_{2C} adrenergic receptors (Ki of 11 nM), is a partial agonist at serotonin 5-HT_{1A} (Ki of 6.4 nM) receptors, and is an antagonist at the α_{2A} adrenergic receptors (Ki of 41 nM). Lurasidone exhibits little or no affinity for histamine H₁ and muscarinic M₁ receptors (IC₅₀ >1,000 nM).

ECG Changes

The effects of lurasidone on the QTc interval were evaluated in a randomized, doubleblind, multiple-dose, parallel-dedicated thorough QT study in 43 patients with schizophrenia or schizoaffective disorder, who were treated with lurasidone hydrochloride tablets doses of 120 mg daily, 600 mg daily and completed the study. The maximum mean (upper 1-sided, 95% CI) increase in baseline- adjusted QTc intervals based on individual correction method (QTcI) was 7.5 (11.7) ms and 4.6 (9.5) ms, for the 120 mg and 600 mg dose groups respectively, observed at 2 to 4 hours after dosing. In this study, there was no apparent dose (exposure)-response relationship.

In short-term, placebo-controlled studies in schizophrenia and bipolar depression, no post- baseline QT prolongations exceeding 500 msec were reported in patients treated with lurasidone hydrochloride tablets or placebo.

12.3 Pharmacokinetics

Adults

The activity of lurasidone is primarily due to the parent drug. The pharmacokinetics of

lurasidone is dose-proportional within a total daily dose range of 20 mg to 160 mg. Steady-state concentrations of lurasidone are reached within 7 days of starting lurasidone hydrochloride tablets.

Following administration of 40 mg of lurasidone hydrochloride tablets, the mean (%CV) elimination half-life was 18 (7) hours.

Absorption and Distribution: Lurasidone is absorbed and reaches peak serum concentrations in approximately 1-3 hours. It is estimated that 9 to 19% of an administered dose is absorbed. Following administration of 40 mg of lurasidone hydrochloride tablets, the mean (%CV) apparent volume of distribution was 6,173 (17.2) L. Lurasidone is highly bound (~99%) to serum proteins.

In a food effect study, lurasidone mean C_{max} and AUC were about 3-times and 2-times, respectively, when administered with food compared to the levels observed under fasting conditions. Lurasidone exposure was not affected as meal size was increased from 350 to 1,000 calories and was independent of meal fat content [see Dosage and Administration (2.3)].

In clinical studies, establishing the safety and efficacy of lurasidone hydrochloride tablets, patients were instructed to take their daily dose with food [see Dosage and Administration (2.3)].

Metabolism and Elimination: Lurasidone is metabolized mainly via CYP3A4. The major biotransformation pathways are oxidative *N*-dealkylation, hydroxylation of norbornane ring, and *S*-oxidation. Lurasidone is metabolized into two active metabolites (ID-14283 and ID-14326) and two major non-active metabolites (ID-20219 and ID-20220). Based on *in vitro* studies, lurasidone is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP4A11, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP2E1 enzymes. Because lurasidone is not a substrate for CYP1A2, smoking is not expected to have an effect on the pharmacokinetics of lurasidone.

Transporter proteins: In vitro studies suggest lurasidone is not a substrate of OATP1B1 or OATP1B3, however, is probably a substrate of P-gp and BCRP. *In vitro* studies indicate that lurasidone is not expected to inhibit transporters OATP1B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, MATE1, MATE2-K and BSEP at clinically relevant concentrations. Lurasidone is not a clinically significant inhibitor of P-gp. However, it may inhibit BCRP.

Total excretion of radioactivity in urine and feces combined was approximately 89%, with about 80% recovered in feces and 9% recovered in urine, after a single dose of [¹⁴C]-labeled lurasidone.


Following administration of 40 mg of lurasidone hydrochloride tablets, the mean (%CV) apparent clearance was 3,902 (18.0) mL/min.

Drug Interaction Studies

Effects of other drugs on the exposure of lurasidone are summarized in Figure 1. A population PK analyses concluded that coadministration of lithium 300 to 2,400 mg/day or valproate 300 to 2,000 mg/day with lurasidone for up to 6 weeks has minimal effect on lurasidone exposure.

And the effects of lurasidone on the exposures of other drugs are summarized in Figure 2. A population PK analyses concluded that coadministration of lurasidone has minimal effect on lithium and valproate exposure when it is coadministered with lithium 300 to 2,400 mg/day or valproate 300 to 2,000 mg/day.


Figure 1: Impact of Other Drugs on Lurasidone Pharmacokinetics



Impact of other drugs on Lurasidone Pharmacokinetics(PK)

Change relative to lurasidone alone





Change relative to Interactive Drug Alone

The effect of intrinsic patient factors on the pharmacokinetics of lurasidone is presented in Figure 3.

Pediatric Patients

Lurasidone exposure (i.e., steady-state C_{max} and AUC) in children and adolescent patients (10 to 17 years of age) was generally similar to that in adults across the dose range from 40 to 160 mg, without adjusting for body weight.




Figure 3: Impact of Other Patient Factors on Lurasidone Pharmacokinetics

* Compare to Caucasian

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis: Lurasidone increased incidences of malignant mammary gland tumors and pituitary gland adenomas in female mice orally dosed with 30, 100, 300, or 650 mg/kg/day. The lowest dose produced plasma levels (AUC) approximately equal to those in humans receiving the MRHD of 160 mg/day. No increases in tumors were seen in male mice up to the highest dose tested, which produced plasma levels (AUC) 14 times those in humans receiving the MRHD.

Lurasidone increased the incidence of mammary gland carcinomas in female rats orally dosed at 12 and 36 mg/kg/day: the lowest dose; 3 mg/kg/day is the no-effect dose

which produced plasma levels (AUC) 0.4 times those in humans receiving the MRHD. No increases in tumors were seen in male rats up to the highest dose tested, which produced plasma levels (AUC) 6 times those in humans receiving the MRHD.

Proliferative and/or neoplastic changes in the mammary and pituitary glands of rodents have been observed following chronic administration of antipsychotic drugs and are considered to be prolactin-mediated [see Warnings and Precautions (5.7)].

Mutagenesis: Lurasidone did not cause mutation or chromosomal aberration when tested *in vitro* and *in vivo test battery*. Lurasidone was negative in the Ames gene mutation test, the Chinese Hamster Lung (CHL) cells, and in the *in vivo* mouse bone marrow micronucleus test up to 2,000 mg/kg which is 61 times the MRHD of 160 mg/day based on mg/m² body surface area.

Impairment of Fertility: Estrus cycle irregularities were seen in rats orally administered lurasidone at 1.5, 15 and 150 mg/kg/day for 15 consecutive days prior to mating, during the mating period, and through gestation day 7. No effect was seen at the lowest dose of 0.1 mg/kg which is approximately 0.006 times the MRHD of 160 mg/day based on mg/m². Fertility was reduced only at the highest dose, which was reversible after a 14 day drug-free period. The no- effect dose for reduced fertility was approximately equal to the MRHD based on mg/m².

Lurasidone had no effect on fertility in male rats treated orally for 64 consecutive days prior to mating and during the mating period at doses up to 9 times the MRHD based on mg/m².

14 CLINICAL STUDIES

14.1 Schizophrenia

Adults

The efficacy of lurasidone for the treatment of schizophrenia was established in five short-term (6-week), placebo-controlled studies in adult patients (mean age of 38.4 years, range 18 to 72) who met DSM-IV criteria for schizophrenia. An active-control arm (olanzapine or quetiapine extended-release) was included in two studies to assess assay sensitivity.

Several instruments were used for assessing psychiatric signs and symptoms in these studies:

- Positive and Negative Syndrome Scale (PANSS), is a multi-item inventory of general psychopathology used to evaluate the effects of drug treatment in schizophrenia. PANSS total scores may range from 30 to 210.
- Brief Psychiatric Rating Scale derived (BPRSd), derived from the PANSS, is a multiitem inventory primarily focusing on positive symptoms of schizophrenia, whereas the PANSS includes a wider range of positive, negative and other symptoms of schizophrenia. The BPRSd consists of 18 items rated on a scale of 1 (not present) to 7 (severe). BPRSd scores may range from 18 to 126.
- 3. The Clinical Global Impression severity scale (CGI-S) is a clinician-rated scale that measures the subject's current illness state on a 1- to 7-point scale.

The endpoint associated with each instrument is change from baseline in the total score to the end of week 6. These changes are then compared to placebo changes for the drug and control groups.

The results of the studies follow:

 Study 1: In a 6-week, placebo-controlled trial (N=145) involving two fixed doses of lurasidone hydrochloride tablets (40 or 120 mg/day), both doses of lurasidone hydrochloride tablets at Endpoint were superior to placebo on the BPRSd total score, and the CGI-S.

- 2. Study 2: In a 6-week, placebo-controlled trial (N=180) involving a fixed dose of lurasidone hydrochloride tablets (80 mg/day), lurasidone hydrochloride tablets at Endpoint was superior to placebo on the BPRSd total score, and the CGI-S.
- 3. Study 3: In a 6-week, placebo- and active-controlled trial (N=473) involving two fixed doses of lurasidone hydrochloride tablets (40 or 120 mg/day) and an active control (olanzapine), both lurasidone hydrochloride tablets doses and the active control at Endpoint were superior to placebo on the PANSS total score, and the CGI-S.
- 4. Study 4: In a 6-week, placebo-controlled trial (N=489) involving three fixed doses of lurasidone hydrochloride tablets (40, 80 or 120 mg/day), only the 80 mg/day dose of lurasidone hydrochloride tablets at Endpoint was superior to placebo on the PANSS total score, and the CGI-S.
- 5. Study 5: In a 6-week, placebo- and active-controlled trial (N=482) involving two fixed doses of lurasidone hydrochloride tablets (80 or 160 mg/day) and an active control (quetiapine extended-release), both lurasidone hydrochloride tablets doses and the active control at Endpoint were superior to placebo on the PANSS total score, and the CGI-S.

Thus, the efficacy of lurasidone hydrochloride tablets at doses of 40, 80, 120 and 160 mg/day has been established (Table 35).

		Primary I	Efficacy Measur	e: BPRSd
Study	Treatment Group	Mean Baseline Score (SD)	LS Mean Change from Baseline (SE)	Placebo- subtracted Difference ^a (95% CI)
	Lurasidone (40 mg/day)*	54.2 (8.8)	-9.4 (1.6)	-5.6 (-9.8, -1.4)
1	Lurasidone (120 mg/day)*	52.7 (7.6)	-11.0 (1.6)	-6.7 (-11.0, -2.5)
	Placebo	54.7 (8.1)	-3.8 (1.6)	-
2	Lurasidone (80 mg/day)*	55.1 (6.0)	-8.9 (1.3)	-4.7 (-8.3, -1.1)
	Placebo	56.1 (6.8)	-4.2 (1.4)	-
		Primary I	Efficacy Measur	e: PANSS
3	Lurasidone (40 mg/day)*	96.6 (10.7)	-25.7 (2.0)	-9.7 (-15.3, -4.1)
	Lurasidone (120 mg/day)*	97.9 (11.3)	-23.6 (2.1)	-7.5 (-13.4, -1.7)
	Olanzapine (15 mg/day)* ^b	96.3 (12.2)	-28.7 (1.9)	-12.6 (-18.2, - 7.9)
	Placebo	95.8 (10.8)	-16.0 (2.1)	-
4	Lurasidone (40 mg/day)	96.5 (11.5)	-19.2 (1.7)	-2.1 (-7.0, 2.8)
	Lurasidone (80 mg/day)*	96.0 (10.8)	-23.4 (1.8)	-6.4 (-11.3, -1.5)
	Lurasidone (120 mg/day)	96.0 (9.7)	-20.5 (1.8)	-3.5 (-8.4, 1.4)
	Placebo	96.8 (11.1)	-17.0 (1.8)	-
5	Lurasidone (80 mg/day)*	97.7 (9.7)	-22.2 (1.8)	-11.9 (-16.9, - 6.9)

Table 35: Primary Efficacy Results for Studies in Adult Patients withSchizophrenia (BPRSd or PANSS Scores)

Lurasidone (160 mg/day)*	97.5 (11.8)	-26.5 (1.8)	-16.2 (-21.2, - 11.2)
Quetiapine Extended- release (600 mg/day)* ^b	97.7 (10.2)	-27.8 (1.8)	-17.5 (-22.5, - 12.4)
Placebo	96.6 (10.2)	-10.3 (1.8)	

SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval, unadjusted for multiple comparisons.

^a Difference (drug minus placebo) in least-squares mean change from baseline.

^b Included for assay sensitivity.

* Doses statistically significantly superior to placebo.

Examination of population subgroups based on age (there were few patients over 65), gender and race did not reveal any clear evidence of differential responsiveness.

Adolescents (13 to 17 years)

The efficacy of lurasidone, was established in a 6-week, multicenter, randomized, double-blind, placebo-controlled study of adolescents (13 to 17 years) who met DSM-IV-TR criteria for schizophrenia (N=326). Patients were randomized to one of two fixed-doses of lurasidone hydrochloride tablets (40 or 80 mg/day) or placebo.

The primary rating instrument used to assess psychiatric signs and symptoms was the PANSS. The key secondary instrument was the CGI-S.

For both dose groups, lurasidone hydrochloride tablet was superior to placebo in reduction of PANSS and CGI-S scores at Week 6. On average, the 80 mg/day dose did not provide additional benefit compared to the 40 mg/day dose.

The primary efficacy results are provided in Table 36.

Table 36: Primary Efficacy Results (PANSS Total Score) for the AdolescentSchizophrenia Study

Treatment Group	o Primary	Efficacy Measu	re: PANSS
	Mean Baseline Score (SD)	LS Mean Change from Baseline (SE)	Placebo- subtracted Difference (95% CI)
Lurasidone (40 mg/day)*	94.5 (10.97)	-18.6 (1.59)	-8.0 (-12.4, -3.7)
Lurasidone (80 mg/day)*	94.0 (11.12)	-18.3 (1.60)	-7.7 (-12.1, -3.4)
Placebo	92.8 (11.08)	-10.5 (1.59)	-

SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval, unadjusted for multiple comparisons.

^a Difference (drug minus placebo) in least-squares mean change from baseline.

* Doses statistically significantly superior to placebo.

14.2 Depressive Episodes Associated with Bipolar I Disorder

Adults

Monotherapy

The efficacy of lurasidone, as monotherapy, was established in a 6-week, multicenter, randomized, double-blind, placebo-controlled study of adult patients (mean age of 41.5 years, range 18 to 74) who met DSM-IV-TR criteria for major depressive episodes associated with bipolar I disorder, with or without rapid cycling, and without psychotic

features (N=485). Patients were randomized to one of two flexible-dose ranges of lurasidone hydrochloride tablets (20 to 60 mg/day, or 80 to 120 mg/day) or placebo.

The primary rating instrument used to assess depressive symptoms in this study was the Montgomery-Asberg Depression Rating Scale (MADRS), a 10-item clinician-rated scale with total scores ranging from 0 (no depressive features) to 60 (maximum score). The primary endpoint was the change from baseline in MADRS score at Week 6. The key secondary instrument was the Clinical Global Impression-Bipolar-Severity of Illness scale (CGI-BP-S), a clinician-rated scale that measures the subject's current illness state on a 7-point scale, where a higher score is associated with greater illness severity.

For both dose groups, lurasidone hydrochloride tablet was superior to placebo in reduction of MADRS and CGI-BP-S scores at Week 6. The primary efficacy results are provided in Table 37. The high dose range (80 to 120 mg per day) did not provide additional efficacy on average, compared to the low dose range (20 to 60 mg per day).

Adjunctive Therapy with Lithium or Valproate

The efficacy of lurasidone, as an adjunctive therapy with lithium or valproate, was established in a 6-week, multicenter, randomized, double-blind, placebo-controlled study of adult patients (mean age of 41.7 years, range 18 to 72) who met DSM-IV-TR criteria for major depressive episodes associated with bipolar I disorder, with or without rapid cycling, and without psychotic features (N=340). Patients who remained symptomatic after treatment with lithium or valproate were randomized to flexibly dosed lurasidone hydrochloride tablets 20 to 120 mg/day or placebo.

The primary rating instrument used to assess depressive symptoms in this study was the MADRS. The primary endpoint was the change from baseline in MADRS score at Week 6. The key secondary instrument was the CGI-BP-S scale.

Lurasidone hydrochloride tablet was superior to placebo in reduction of MADRS and CGI-BP-S scores at Week 6, as an adjunctive therapy with lithium or valproate (Table 37).

		Primary E	Efficacy Measur	e: MADRS
Study	Treatment Group	Mean Baseline Score (SD)	LS Mean Change from Baseline (SE)	Placebo- subtracted Difference ^a (95% CI)
Manatharan	Lurasidone (20 to 60 mg/day)*	30.3 (5.0)	-15.4 (0.8)	-4.6 (-6.9, -2.3)
Monotherapy study	^y Lurasidone (80 to 120 mg/day)*	30.6 (4.9)	-15.4 (0.8)	-4.6 (-6.9, -2.3)
	Placebo	30.5 (5.0)	-10.7 (0.8)	-
Adjunctive Therapy	Lurasidone (20 to 120 mg/day)* + lithium or valproate	30.6 (5.3)	-17.1 (0.9)	-3.6 (-6.0, -1.1)
study	Placebo + lithium or valproate	30.8 (4.8)	-13.5 (0.9)	-

Table 37: Primary Efficacy Results for Adult Studies in Depressive EpisodesAssociated with Bipolar I Disorder (MADRS Scores)

SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval, unadjusted for multiple comparisons.

^a Difference (drug minus placebo) in least-squares mean change from baseline. * Treatment group statistically significantly superior to placebo.

Pediatric Patients (10 to 17 years)

The efficacy of lurasidone was established in a 6-week, multicenter, randomized, double-

blind, placebo-controlled study of pediatric patients (10 to 17 years) who met DSM-5 criteria for a major depressive episode associated with bipolar I disorder, with or without rapid cycling, and without psychotic features (N=343). Patients were randomized to flexibly dosed lurasidone hydrochloride tablets 20 to 80 mg/day or placebo. At the end of the clinical study, most patients (67%) received 20 mg/day or 40 mg/day.

The primary rating scale used to assess depressive symptoms in this study was the Children's Depression Rating Scale, Revised (CDRS-R) total score. The CDRS-R is a 17item clinician- rated scale with total scores ranging from 17 to 113. The primary endpoint was the change from baseline in CDRS-R score at Week 6. The key secondary endpoint was the change from baseline in CGI-BP-S depression score.

Lurasidone hydrochloride tablet was superior to placebo in reduction of CDRS-R total score and CGI-BP-S depression score at Week 6. The primary efficacy results are provided in Table 38.

Table 38 Primary Efficacy Results for the Study in Depressive Episodes Associated with Bipolar I Disorder (CDRS-R Total Score) in Pediatric Patients (10 to 17 years)

Treatment Group	Primary Efficacy Measure: CDRS-R		
	Mean Baseline Score (SD)	LS Mean Change from Baseline (SE)	Placebo- subtracted Difference ^a (95% CI)
Lurasidone (20 to 80 mg/day)*	59.2 (8.24)	-21.0 (1.06)	-5.7 (-8.4, -3.0)
Placebo	58.6 (8.26)	-15.3 (1.08)	-

SD: standard deviation; SE: standard error; LS Mean: least-squares mean; CI: confidence interval, unadjusted for multiple comparisons.

^a Difference (drug minus placebo) in least-squares mean change from baseline.

* Treatment group statistically significantly superior to placebo.

16 HOW SUPPLIED/STORAGE AND HANDLING

Lurasidone Hydrochloride Tablets 20 mg are available as white to off-white, round shaped film coated tablet, debossed "335" on one side and plain on the reverse side. They are supplied as follows:

Bottles of 30: NDC 23155-887-03

Bottles of 90: NDC 23155-887-09 Bottles of 500: NDC 23155-887-05 Bulk Pack: NDC 23155-887-18

Lurasidone Hydrochloride Tablets 40 mg are available as white to off-white, round shaped film coated tablet, debossed "336" on one side and plain on the reverse side. They are supplied as follows:

Bottles of 30: NDC 23155-888-03

Bottles of 90: NDC 23155-888-09 Bottles of 500: NDC 23155-888-05 Bulk Pack: NDC 23155-888-18

Lurasidone Hydrochloride Tablets 60 mg are available as white to off-white, capsule shaped film coated tablet, debossed "337" on one side and plain on reverse side. They are supplied as follows:

Bottles of 30: NDC 23155-889-03

Bottles of 90: NDC 23155-889-09 Bottles of 500: NDC 23155-889-05 Bulk Pack: NDC 23155-889-18

Lurasidone Hydrochloride Tablets 80 mg are available as white to off-white, oval shaped film coated tablet, debossed "338" on one side and plain on the reverse side. They are supplied as follows:

Bottles of 30: NDC 23155-890-03

Bottles of 90: NDC 23155-890-09 Bottles of 500: NDC 23155-890-05 Bulk Pack: NDC 23155-890-18

Lurasidone Hydrochloride Tablets 120 mg are available as white to off-white, oval shaped film coated tablet, debossed "339" on one side and plain on reverse side. They are supplied as follows:

Bottles of 30: NDC 23155-891-03 Bottles of 100: NDC 23155-891-01 Bottles of 500: NDC 23155-891-05 Bottles of 1000: NDC 23155-891-10 Bulk pack: NDC 23155-891-18

<u>Storage</u>

Store lurasidone hydrochloride tablets at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature].

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Suicidal Thoughts and Behavior

Advise patients and caregivers to look for the emergence of suicidality, especially early during treatment and when the dosage is adjusted up or down and instruct them to report such symptoms to the healthcare provider [see Boxed Warning, Warnings and Precautions (5.2)].

Neuroleptic Malignant Syndrome

Counsel patients about a potentially fatal adverse reaction referred to as Neuroleptic Malignant Syndrome (NMS). Advise patients, family members, or caregivers to contact healthcare provider or to report to the emergency room if they experience signs and symptoms of NMS [see Warnings and Precautions (5.4)].

Tardive Dyskinesia

Counsel patients on the signs and symptoms of tardive dyskinesia and to contact their healthcare provider if these abnormal movements occur [see Warnings and Precautions (5.5)].

Metabolic Changes

Educate patients about the risk of metabolic changes, how to recognize symptoms of hyperglycemia and diabetes mellitus, and the need for specific monitoring, including blood glucose, lipids, and weight [see Warnings and Precautions (5.6)].

Hyperprolactinemia

Counsel patients on signs and symptoms of hyperprolactinemia that may be associated with chronic use of lurasidone hydrochloride tablets. Advise them to seek medical

attention if they experience any of the following: amenorrhea or galactorrhea in females, erectile dysfunction or gynecomastia in males [see Warnings and Precautions (5.7)].

Leukopenia/Neutropenia

Advise patients with a pre-existing low WBC or a history of drug-induced leukopenia/neutropenia that they should have their CBC monitored while taking lurasidone hydrochloride tablets [see Warnings and Precautions (5.8)].

Orthostatic Hypotension

Educate patients about the risk of orthostatic hypotension, particularly at the time of initiating treatment, re-initiating treatment, or increasing the dose [see Warnings and *Precautions (5.9)*].

Interference with Cognitive and Motor Performance

Caution patients about performing activities requiring mental alertness, such as operating hazardous machinery or operating a motor vehicle, until they are reasonably certain that lurasidone hydrochloride tablets therapy does not affect them adversely *[see Warnings and Precautions (5.12)]*.

Heat Exposure and Dehydration

Educate patients regarding appropriate care in avoiding overheating and dehydration [see Warnings and Precautions (5.13)].

Activation of Mania or Hypomania

Advise patients and their caregivers to observe for signs of activation of mania/hypomania [see Warnings and Precautions (5.14)].

Concomitant Medication

Advise patients to inform their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs, because there is a potential for drug interactions *[see Drug Interactions (7)]*.

<u>Pregnancy</u>

Advise patients that lurasidone hydrochloride tablets may cause extrapyramidal and/or withdrawal symptoms in a neonate. Advise patients to notify their healthcare provider with a known or suspected pregnancy [see Use in Specific Populations (8.1)]. Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lurasidone hydrochloride tablets during pregnancy [see Use in Specific Populations (8.1)].

Dispense with Medication Guide available at: www.avetpharma.com/product

Distributed by:

Avet Pharmaceuticals Inc.

East Brunswick, NJ 08816

1.866.901.DRUG (3784)

++ Avet Pharma

Revised: 09/2024

MEDICATION GUIDE

MEDICATION GUIDE Lurasidone Hydrochloride Tablets

What is the most important information I should know about Lurasidone Hydrochloride Tablets?

Lurasidone hydrochloride tablets may cause serious side effects, including:

- Increased risk of death in elderly people with dementia-related psychosis. Medicines like lurasidone hydrochloride tablets can raise the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). Lurasidone hydrochloride tablets are not approved for the treatment of people with dementia-related psychosis.
- Increased risk of suicidal thoughts or actions in children and young adults. Antidepressant medicines may increase suicidal thoughts or actions in some children and young adults within the first few months of treatment and when the dose is changed.
 - Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) depression, bipolar illness (also called manic-depressive illness), or a history of suicidal thoughts or actions.

How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?

- Pay close attention to any changes, especially sudden changes in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.
- Call the healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.
- Keep all follow-up visits with the healthcare provider as scheduled. Call the healthcare provider between visits as needed, especially if you have concerns about symptoms.

Call a healthcare provider right away if you or your family member has any of the following symptoms, especially if they are new, worse, or worry you:

- thoughts about suicide or dying
- new or worse depression
- feeling very agitated or restless
- trouble sleeping (insomnia)

- attempts to commit suicide
- new or worse anxiety
- panic attacks
- new or worse irritability
- acting aggressive, being angry, or violent acting on dangerous impulses
 - other unusual changes in behavior or mood
- an extreme increase in activity and talking (mania)

What is Lurasidone Hydrochloride Tablets?

Lurasidone hydrochloride tablet is a prescription medicine used:

- To treat people 13 years of age or older with schizophrenia.
- Alone to treat people 10 years of age and older with depressive episodes that happen with Bipolar I Disorder (bipolar depression).
- With the medicine lithium or valproate to treat adults with depressive episodes that happen with Bipolar I Disorder (bipolar depression).

It is not known if lurasidone hydrochloride tablets are safe and effective in children:

- less than 13 years of age with schizophrenia
- less than 10 years of age with bipolar depression
- for the treatment of irritability associated with autistic disorder

Do not take Lurasidone Hydrochloride Tablets if you are:

- allergic to lurasidone hydrochloride or any of the ingredients in lurasidone hydrochloride tablets. See the end of this Medication Guide for a complete list of ingredients in lurasidone hydrochloride tablets.
- taking certain other medicines called CYP3A4 inhibitors or inducers including ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, rifampin, avasimibe, St. John's wort, phenytoin, or carbamazepine. Ask your healthcare provider if you are not sure if you are taking any of these medicines.

Before taking lurasidone hydrochloride tablets, tell your healthcare provider about all of your medical conditions, including if you:

- have or have had heart problems or stroke
- have or have had low or high blood pressure
- have or have had diabetes or high blood sugar, or have a family history of diabetes or high blood sugar.
- have or have had high levels of total cholesterol or triglycerides
- have or have had high prolactin levels
- have or have had low white blood cell count
- have or have had seizures
- have or have had kidney or liver problems
- are pregnant or plan to become pregnant. It is not known if lurasidone hydrochloride tablets will harm your unborn baby. Talk to your healthcare provider about the risk to your unborn baby if you take lurasidone hydrochloride tablets during pregnancy.
 - Tell your healthcare provider if you become pregnant or think you are pregnant during treatment with lurasidone hydrochloride tablets.
 - If you become pregnant during treatment with lurasidone hydrochloride tablets, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics. You can register by calling 1-866-961-2388 or go to http://womensmentalhealth.org/clinical-andresearchprograms/pregnancyregistry/.
- are breastfeeding or plan to breastfeed. It is not known if lurasidone hydrochloride passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with lurasidone hydrochloride tablets.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Lurasidone hydrochloride tablets and other medicines may affect each other causing possible serious side effects. Lurasidone hydrochloride tablet may affect the way other medicines work, and other medicines may affect how lurasidone hydrochloride tablet works.

Your healthcare provider can tell you if it is safe to take lurasidone hydrochloride tablets with your other medicines. Do not start or stop any other medicines during treatment with lurasidone hydrochloride tablets without talking to your healthcare provider first. Know the medicines you take. Keep a list of your medicines to show your healthcare provider and pharmacist when you get a new medicine.

How should I take Lurasidone Hydrochloride Tablets?

- Take lurasidone hydrochloride tablets exactly as your healthcare provider tells you to take it. Do not change the dose or stop taking lurasidone hydrochloride tablets without first talking to your healthcare provider.
- Take lurasidone hydrochloride tablet by mouth, with food (at least 350 calories).
- If you take too much lurasidone hydrochloride tablets, call your healthcare provider or poison control center or go to the nearest hospital emergency room right away.

What should I avoid while taking Lurasidone Hydrochloride Tablets?

• Do not drive, operate heavy machinery, or do other dangerous activities until you know how lurasidone hydrochloride tablet affects you. Lurasidone hydrochloride

tablets may make you drowsy.

- Avoid eating grapefruit or drinking grapefruit juice during treatment with lurasidone hydrochloride tablets. Grapefruit and grapefruit juice may affect the amount of lurasidone in your blood.
- Do not become too hot or dehydrated during treatment with lurasidone hydrochloride tablets.
 - Do not exercise too much.
 - In hot weather, stay inside in a cool place if possible.
 - Stay out of the sun.
 - $\circ~$ Do not wear too much clothing or heavy clothing.
 - Drink plenty of water.

What are the possible side effects of Lurasidone Hydrochloride Tablets? Lurasidone Hydrochloride Tablets may cause serious side effects, including:

- See "What is the most important information I should know about Lurasidone Hydrochloride Tablets?"
- Stroke (cerebrovascular problems) in elderly people with dementia-related psychosis that can lead to death.
- Neuroleptic malignant syndrome (NMS) a serious condition that can lead to death. Call your healthcare provider or go to the nearest hospital emergency room right away if you have some or all of the following signs and symptoms of NMS:
- high fever

• stiff muscles

confusion

- increased sweating
- changes in your breathing, heart rate, and blood pressure
- **Uncontrolled body movements (tardive dyskinesia).** Lurasidone hydrochloride tablets may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop taking lurasidone hydrochloride tablets. Tardive dyskinesia may also start after you stop taking lurasidone hydrochloride tablets.
- Problems with your metabolism such as:
 - high blood sugar (hyperglycemia) and diabetes. Increases in blood sugar can happen in some people who take lurasidone hydrochloride tablets. Extremely high blood sugar can lead to coma or death. If you have diabetes or risk factors for diabetes (such as being overweight or a family history of diabetes), your healthcare provider should check your blood sugar before you start and during treatment with lurasidone hydrochloride tablets.

Call your healthcare provider if you have any of these symptoms of high blood sugar during treatment with lurasidone hydrochloride tablets:

- feel very thirsty
- feel very hungry
- feel sick to your stomach

- need to urinate more than usual
- feel weak or tired
- feel confused, or your breath smells fruity
- $\circ~$ increased fat levels (cholesterol and triglycerides) in your blood.
- **weight gain.** You and your healthcare provider should check your weight regularly during treatment with lurasidone hydrochloride tablets.
- Increased prolactin levels in your blood (hyperprolactinemia). Your healthcare provider may do blood tests to check your prolactin levels during

treatment with lurasidone hydrochloride tablets. Tell your healthcare provider if you have any of the following signs and symptoms of hyperprolactinemia:

Females:

- absence of your menstrual cycle
- secretion of breast milk when you are not breastfeeding

Males:

- problems getting or maintaining an erection (erectile dysfunction)
- enlargement of breasts (gynecomastia)
- Low white blood cell count. Your healthcare provider may do blood tests during the first few months of treatment with lurasidone hydrochloride tablets.
- **Decreased blood pressure (orthostatic hypotension).** You may feel lightheaded or faint when you rise too quickly from a sitting or lying position.
- **Falls.** Lurasidone hydrochloride tablets may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position (orthostatic hypotension), and can slow your thinking and motor skills which may lead to falls that can cause fractures or other injuries.
- Seizures (convulsions)
- **Problems controlling your body temperature so that you feel too warm.** See "What should I avoid while taking Lurasidone Hydrochloride Tablets?"
- **Mania or hypomania** (manic episodes) in people with a history of bipolar disorder. Symptoms may include:
- greatly increased energy

racing thoughts

- severe problems sleeping
- reckless behavior
 excessive happiness or irritability
- unusually grand ideas
- talking more or faster than usual
- Difficulty swallowing

The most common side effects of Lurasidone Hydrochloride Tablets include:

• Adults with schizophrenia:

- $\circ~$ sleepiness or drowsiness
- restlessness and feeling like you need to move around (akathisia)
- difficulty moving, slow movements, muscle stiffness, or tremor
- nausea

• Children 13 to 17 years of age with schizophrenia:

- sleepiness or drowsiness
- nausea
- restlessness and feeling like you need to move around (akathisia)
- · difficulty moving, slow movements, muscle stiffness, or tremor
- runny nose
- vomiting

• Adults with bipolar depression:

- restlessness and feeling like you need to move around (akathisia)
- difficulty moving, slow movements, muscle stiffness, or tremor
- sleepiness or drowsiness
- Children 10 to 17 years of age with bipolar depression:
 - Nausea
 - weight gain
 - problems sleeping (insomnia)

These are not all of the possible side effects of Lurasidone Hydrochloride Tablets. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store Lurasidone Hydrochloride Tablets?

- Store lurasidone hydrochloride tablets at 20°C to 25°C (68°F to 77°F).
- Keep lurasidone hydrochloride tablets and all medicines out of the reach of children.

General information about the safe and effective use of lurasidone hydrochloride tablets.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use lurasidone hydrochloride tablets for a condition for which it was not prescribed. Do not give lurasidone hydrochloride tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about lurasidone hydrochloride tablets that is written for health professionals.

What are the ingredients in lurasidone hydrochloride tablets? Active ingredient: lurasidone hydrochloride

Inactive ingredients: croscarmellose sodium, hypromellose, magnesium stearate, mannitol, polyethylene glycol, pregelatinized starch and titanium dioxide. Distributed by:

Avet Pharmaceuticals Inc.

East Brunswick, NJ 08816 1.866.901.DRUG (3784)



This Medication Guide has been approved by the U.S. Food and Drug Administration.

51U000000453US01 Revised: 09/2023

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 20 mg

Lurasidone Hydrochloride Tablets 20 mg

NDC Number: 23155-887-18

Caution: For manufacturing, processing and repacking

Rx Only

Lurasidone Hydrochloride Tablets 20 mg		0
Batch No : LLLLLL	Quantity : 10 Kg	
Mfg. Date : YYYY/MM	Approx.: 121,000 Tal	olets
Package Before Date: YYYY/MM/DD		
NDC Number : 23155-887-18	Rx Only	
Storage : Preserve in tight containers.Store a excursions permitted between 15° [See USP Controlled Room Temper Caution : For manufacturing, processing or r	to 30°C(59° to 86°F) rature]	
Manufactu	red By:	-
Avet Pharmaceutic		

Lurasidone Hydrochloride Tablets

20 mg

PHARMACIST: Dispense the Medication Guide provided at www.avetpharma.com separately to each patient.

90 Tablets

Rx only



NDC 23155-887-03

Lurasidone Hydrochloride Tablets

20 mg

PHARMACIST: Dispense the Medication Guide provided at www.avetpharma.com separately to each patient.

30 Tablets

Rx only



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 40 mg

Lurasidone Hydrochloride Tablets 40 mg

NDC Number: 23155-888-18

Caution: For manufacturing, processing and repacking

Rx Only

Lurasidone Hydrochloride Tablets 40 mg	
atch No : LLLLLLL Quantity : 10 Kg	
Mfg. Date : YYYY/MM	Approx.: 60,500 Tablets
Package Before Date: YYYY/MM/DD NDC Number : 23155-888-18	Rx Only
Storage : Preserve in tight containers.Stor excursions permitted between 1 [See USP Controlled Room Tem] Caution : For manufacturing, processing o	5° to 30°C(59° to 86°F) perature]

NDC 23155-888-09

Lurasidone Hydrochloride Tablets

40 mg

PHARMACIST: Dispense the Medication Guide provided at www.avetpharma.com separately to each patient.

90 Tablets

Rx only



NDC 23155-888-03

Lurasidone Hydrochloride Tablets

40 mg

PHARMACIST: Dispense the Medication Guide provided at www.avetpharma.com separately to each patient.

30 Tablets

Rx only



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 60 mg

Lurasidone Hydrochloride Tablets 60 mg

NDC Number: 23155-889-18

Caution: For manufacturing, processing and repacking

Rx Only

Lurasidone Hydrochlorid	e Tablets 60 mg	0
Batch No : LLLLLLL Mfg. Date : YYYY/MM Package Before Date: YYYY/MM/DD NDC Number : 23155-889-18	Quantity : 10 Approx.: 40,0 Rx Only	-
Storage : Preserve in tight containers.Store at excursions permitted between 15° to [See USP Controlled Room Tempera Caution : For manufacturing, processing or re	o 30°C(59° to 86°F) iture]	;
Manufacture Avet Pharmaceutica		

NDC 23155-889-09

Lurasidone Hydrochloride Tablets

60 mg

PHARMACIST: Dispense the Medication Guide provided at www.avetpharma.com separately to each patient.

90 Tablets

Rx only



NDC 23155-889-03

Lurasidone Hydrochloride Tablets

60 mg

PHARMACIST: Dispense the Medication Guide provided at www.avetpharma.com separately to each patient.

30 Tablets

Rx only



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 80 mg

Lurasidone Hydrochloride Tablets 80 mg

NDC Number: 23155-890-18

Caution: For manufacturing, processing and repacking

Rx Only

	e Tablets 80 mg O
Batch No : LLLLLLL Mfg. Date : YYYY/MM Package Before Date: YYYY/MM/DD NDC Number : 23155-890-18	Quantity : 10 Kg Approx.: 30,000 Tablets Rx Only
Storage : Preserve in tight containers.Store at excursions permitted between 15° to [See USP Controlled Room Tempera	30°C(59° to 86°F)
Caution : For manufacturing, processing or re	epacking

NDC 23155-890-09

Lurasidone Hydrochloride Tablets

80 mg

PHARMACIST: Dispense the Medication Guide provided at www.avetpharma.com separately to each patient.

90 Tablets

Rx only



NDC 23155-890-03

Lurasidone Hydrochloride Tablets

80 mg

PHARMACIST: Dispense the Medication Guide provided at www.avetpharma.com separately to each patient.

30 Tablets

Rx only



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL - 120 mg

Lurasidone Hydrochloride Tablets 120 mg

NDC Number: 23155-891-18

Caution: For manufacturing, processing and repacking

Rx Only

de Tablets 120 mg O
Quantity : 10 Kg
Approx.: 20,000 Tablets
Rx Only
at 20° to 25°C(68° to 77°F); ' to 30°C(59° to 86°F) erature] repacking
ired By: icals Labs Inc.

NDC 23155-891-03

Lurasidone Hydrochloride Tablets

120 mg

PHARMACIST: Dispense the Medication Guide provided at www.avetpharma.com separately to each patient.

30 Tablets

Rx only

NDC 23155-891-03 Lurasidone Hydrochloride Tablets 120 mg PHARMACIST: Dispense the Medication Guide provided at www.avetpharma.com separately to each patient.	to 111.73 mg of lurasidone). to 111.73 mg of lurasidone). See accompanying t for complete prescribing tight, light-resistant efined in the USP using a closure. rightly closed. 25°C (68° to 77°F) trolled Room Temperature]. D ALL MEDICATIONS OUT H OF CHILDREN. K, NU 08816 UG (3784) 6US01 Rev. 09/2023 6US01 Rev. 09/2023 4	n Varnished Area*
30 Tablets Rx only	tablet co squivalent I Dosage gge inserge mation. I Dosage in a ation. I nusp containe containe containe inter as d inter as d inter as d inter as d 0000440000000000000000000000000000000	Non
🛟 Avet Pharma®	Each tal HCI (equ Usual D package informaal Dispens Store a Store a Vuel Ph Distribu Distribu Avet Ph Distribu S 51U000 51U000 51U000 3 3	

lurasidone hydrochl						
Product Informa	ation					
Product Type		HUMAN PRESCRIPTION DRUG	ltem C	ode (Source)	NDC:2	3155-887
Route of Administr	ation	ORAL				
Active Ingredien	t/Active I	Moiety				
	Ingred	ient Name		Basis of Stre	ngth	Strengt
LURASIDONE HYDROC UNII:22IC88528T)	CHLORIDE (U	JNII: O0P4I5851I) (LURASIDONE -		LURAS IDONE HYDROCHLORIDE		20 mg
Inactive Ingredie	ents					
		Ingredient Name			St	trength
CROSCARMELLOSE S	ODIUM (UNII	: M28OL1HH48)				
HYPROMELLOSES (UN	III: 3NXW29V3	3WO)				
MAGNESIUM STEARA	TE (UNII: 700	97M6I30)				
MANNITOL (UNII: 30W	_53L36A)					
POLYETHYLENE GLYC	OL, UNSPE	CIFIED (UNII: 3WJQ0SDW1A)				
STARCH, CORN (UNII:						
TITANIUM DIOXIDE (U	INII: 15FIX9V2	JP)				
Product Charact	eristics					
Color	white (white t	o off-white)	Score		no s	core
Shape F	ROUND		Size		6mm	1
Flavor			Imprint	t Code	335	
Contains						

Ρ	Packaging						
#	ltem Code	Package Description	Marketing Start Date	Marketing End Date			
1	NDC:23155- 887-18	121000 in 1 CONTAINER; Type 0: Not a Combination Product	10/19/2023				
2	NDC:23155- 887-09	90 in 1 BOTTLE; Type 0: Not a Combination Product	10/19/2023	03/30/2025			
3	NDC:23155- 887-05	500 in 1 BOTTLE; Type 0: Not a Combination Product	10/19/2023	03/30/2025			

4 NDC:23155- 887-03	30 in 1 BOTTLE Product	; Type 0: Not a Combination	10/19/	2023		
Marketing	Informat	ion				
Marketing Category		tion Number or Monograph Citation	Mar	keting Start Date		ting End ate
ANDA	ANDA20805	8	10/19/	2023		
		OCHLORIDE				
lurasidone hydr						
Product Info	ormation					
Product Type		HUMAN PRESCRIPTION DRUG	ltem C	ode (Source)	NDC:2	3155-888
Route of Admin	nistration	ORAL				
Nouce of Admin						
Active Ingred	dient/Active	Moietv				
Active higher		dient Name		Basis of St	renath	Strength
LURASIDONE HY	-	UNII: O0P4I5851I) (LURASIDONE -			rengtn	
UNII:22IC88528T)				HYDROCHLORIDE		40 mg
In a still a linear	a dia mta					
Inactive Ingr	ealents	Ingradient Neme			C	wo ng th
CROSCARMELLO					51	rength
HYPROMELLOSE						
MAGNESIUM STE	•					
MANNITOL (UNII:	30WL53L36A)					
POLYETHYLENE	GLYCOL, UNSPE	CIFIED (UNII: 3WJQ0SDW1A)				
STARCH, CORN (UNII: O8232NY3S])				
TITANIUM DIOXI	DE (UNII: 15FIX9V	2JP)				
Product Cha						
Color Shape	white (white ROUND		Score Size		no so 8mm	
Flavor	ROOND		Imprint	Code	336	
Contains			mprint	Coue	550	
contains						
Dackaging						
Packaging			Mor	kating Start	Marka	ting End
# Item Code	Pa	ckage Description	Mar	keting Start Date		ting End ate
1 NDC:23155- 888-18	60500 in 1 CON Product	ITAINER; Type 0: Not a Combination	¹ 10/19/2	2023		
2 NDC:23155- 888-09	90 in 1 BOTTLE Product	; Type 0: Not a Combination	10/19/2	2023	03/30/202	5
3 NDC:23155- 888-05	500 in 1 BOTTL Product	E; Type 0: Not a Combination	10/19/2	2023	03/30/202	5
4 NDC:23155- 888-03	30 in 1 BOTTLE Product	; Type 0: Not a Combination	10/19/2	2023		

Μ	larketing	Informat	ion				
	Marketing Category		tion Number or Monograph Citation	Mai	rketing Start Date		ting End ate
AN	IDA	ANDA20805	8	10/19/	/2023		
			DCHLORIDE				
lur	asidone hydro	ochioride table	et, film coated				
Ρ	roduct Info	rmation					
Pı	roduct Type		HUMAN PRESCRIPTION DRUG	ltem C	Code (Source)	NDC:2	3155-889
Ro	oute of Admin	istration	ORAL				
Δ	ctive Ingred	lient/Active	Moiety				
			dient Name		Basis of St	rength	Strengt
	Irasidone Hyd III:22IC88528T)	-	(UNII: O0P4I5851I) (LURASIDONE -		LURAS IDONE HYDROCHLORIDE		60 mg
1							
In	active Ingre	edients	Ingredient Name			51	trength
CF	ROSCARMELLOS	SE SODIUM (UN	-				liengtii
	PROMELLOSES						
M	AGNESIUM STE	ARATE (UNII: 70	097M6I30)				
M	ANNITOL (UNII: 3	30WL53L36A)					
			CIFIED (UNII: 3WJQ0SDW1A)				
	ARCH, CORN (U		-				
TI	TANIUM DIOXID	E (UNII: 15FIX9V	2JP)				
Pı	roduct Char	acteristics					
	olor		to off-white)	Score		no se	core
	паре	CAPSULE		Size		no score 13mm	
	avor			Imprin	t Code	337	
Co	ontains						
D	ackaging						
#	Item Code	Pa	ckage Description	Mar	keting Start		ting End
1	NDC:23155-	40000 in 1 COM	TAINER; Type 0: Not a Combination	^۱ 10/19/	Date 2023	D	ate
-	889-18 NDC:23155-		; Type 0: Not a Combination	10/19/2023		03/30/202	5
3	889-09 NDC:23155- 889-05	Product 500 in 1 BOTTL Product	E; Type 0: Not a Combination	10/19/		03/30/202	
4	NDC:23155- 889-03		; Type 0: Not a Combination	10/19/	2023		
Μ	larketing	Informat	ion				
	Marketing Category		tion Number or Monograph Citation	Ма	rketing Start Date		ting End ate

			DCHLORIDE et, film coated				
Ρ	roduct Info	rmation					
Pı	roduct Type		HUMAN PRESCRIPTION DRUG	ltem C	Code (Source)	NDC:2	23155-890
	Route of Administration ORAL ORAL						
A	ctive Ingred	ient/Active	Moiety				
		Ingre	dient Name		Basis of St	trength	Strength
	I RASIDONE HYD IIII:22IC88528T)		(UNII: O0P4I5851I) (LURASIDONE -		LURAS IDONE HYDROCHLORIDE	E	80 mg
In	active Ingre	edients					
			Ingredient Name			S	trength
		-	II: M280L1HH48)				
	PROMELLOSES	-					
MAGNESIUM STEARATE (UNII: 70097M6I30)							
MANNITOL (UNII: 30WL53L36A)							
PC	LYETHYLENE (GLYCOL, UNSPE	ECIFIED (UNII: 3WJQ0SDW1A)				
PC ST		GLYCOL, UNSPE JNII: 08232NY3S	J)				
PC ST	ARCH, CORN (U	GLYCOL, UNSPE JNII: 08232NY3S	J)				
PC ST TI	ARCH, CORN (U	GLYCOL, UNSPE JNII: 08232NY3S De (UNII: 15FIX9V	J)				
PC ST TI	DLYETHYLENE C ARCH, CORN (U TANIUM DIOXID	GLYCOL, UNSPE JNII: 08232NY3S De (UNII: 15FIX9V	J) (2JP)	Score		no s	core
PC ST TI PI Cc Sr	OLYETHYLENE C ARCH, CORN (L TANIUM DIOXID roduct Char blor hape	GLYCOL, UNSPE JNII: 08232NY3S DE (UNII: 15FIX9V acteristics	J) (2JP)	Score Size		no s 12m	
PC ST TI PI Cc Sł Fli	ARCH, CORN (U TANIUM DIOXID roduct Char blor hape avor	GLYCOL, UNSPE JNII: 08232NY3S DE (UNII: 15FIX9V CACTERISTICS white (white	J) (2JP)		t Code		
PC ST TI PI Cc Sł Fli	OLYETHYLENE C ARCH, CORN (L TANIUM DIOXID roduct Char blor hape	GLYCOL, UNSPE JNII: 08232NY3S DE (UNII: 15FIX9V CACTERISTICS white (white	J) (2JP)	Size	t Code	12m	
PC ST TI Cc SI Fla Cc	ARCH, CORN (U TANIUM DIOXID roduct Char blor hape avor	GLYCOL, UNSPE JNII: 08232NY3S DE (UNII: 15FIX9V CACTERISTICS white (white	J) (2JP)	Size Imprint		12m	
PC ST TI Cc Sr Fli Cc	OLYETHYLENE C ARCH, CORN (L TANIUM DIOXID roduct Char blor hape avor ontains	ACTENDED OF A CONTRACT OF A CO	J) (2JP)	Size Imprint	t Code keting Start Date	12m 338 Marke	
PC ST TI Cc Sh Fla Cc Pa #	ackaging	ACCOL, UNSPE JNII: 08232NY3S (UNII: 15FIX9V ACCORTISTICS white (white OVAL Pa	J) (2JP) to off-white)	Size Imprint Mar	keting Start Date	12m 338 Marke	m ting End
PC ST TI Cc SI Fla Cc	ARCH, CORN (UTANIUM DIOXID roduct Char blor hape avor bntains ackaging item Code NDC:23155-	ACCOL, UNSPE JNII: 08232NY3S E (UNII: 15FIX9V ACCEPTISTICS white (white OVAL OVAL Pa 30000 in 1 COM Product 90 in 1 BOTTLE Product	J) (2JP) to off-white) ckage Description JTAINER; Type 0: Not a Combination ;; Type 0: Not a Combination	Size Imprint Mar	keting Start Date 2023	12m 338 Marke	n ting End Pate
PC ST TI CC SF Fla CC Pa # 1	ARCH, CORN (U TANIUM DIOXID roduct Char blor hape avor ontains Ackaging Item Code NDC:23155- 890-18 NDC:23155- 890-09 NDC:23155- 890-09	ACTENTISTICS White (White OVAL COV	J) (2JP) to off-white) ckage Description JTAINER; Type 0: Not a Combination ;; Type 0: Not a Combination E; Type 0: Not a Combination	Size Imprint Mar	keting Start Date 2023 2023	12m 338 Marke	m ting End pate
PC ST TI CC SF FI CC P i 4 1 2 3	ARCH, CORN (U TANIUM DIOXID roduct Char olor ape avor ontains ackaging Item Code NDC:23155- 890-18 NDC:23155- 890-09 NDC:23155-	ACTENTISTICS White (White OVAL COV	J) (2JP) to off-white) ckage Description JTAINER; Type 0: Not a Combination ;; Type 0: Not a Combination	Size Imprint Mar 10/19/ 10/19/	keting Start Date 2023 2023 2023	12m 338 Marke D 03/30/202	m ting End pate
PC ST TI Cc Sh Fii Cc Pi 4 2 3 4	ARCH, CORN (U TANIUM DIOXID roduct Char olor ape avor ontains Ackaging Item Code NDC:23155- 890-18 NDC:23155- 890-09 NDC:23155- 890-05 NDC:23155-	ACCEPTISTICS White (White OVAL COVAL	J) (2JP) to off-white) ckage Description JTAINER; Type 0: Not a Combination ;; Type 0: Not a Combination ;; Type 0: Not a Combination ;; Type 0: Not a Combination	Size Imprint Mar 10/19/ 10/19/ 10/19/	keting Start Date 2023 2023 2023	12m 338 Marke D 03/30/202	m ting End pate
PC ST TI PI CC SF FI CC Pi # 1 2 3 4	Arch, Corn (C TANIUM DIOXID roduct Char blor hape avor ontains Ackaging Item Code NDC:23155- 890-09 NDC:23155- 890-05 NDC:23155- 890-05 NDC:23155- 890-03	ACCOLDENSION OF CONTRACT OF CO	J) (2JP) to off-white) ckage Description JTAINER; Type 0: Not a Combination ;; Type 0: Not a Combination ;; Type 0: Not a Combination ;; Type 0: Not a Combination	Size Imprint Mar 10/19/ 10/19/ 10/19/	keting Start Date 2023 2023 2023	12m 338 Marke D 03/30/202 03/30/202	m ting End pate

10/19/2023

ANDA

ANDA208058

_							
Ρ	roduct Info	rmation					
Pı	roduct Type		HUMAN PRESCRIPTION DRUG	ltem C	ode (Source)	NDC:2	23155-891
Re	oute of Admin	istration	ORAL				
4	ctive Ingred	lient/Active	Moiety				
		Ingre	dient Name		Basis of St	rength	Strengt
	IRASIDONE HYE IIII:22IC88528T)	DROCHLORIDE	(UNII: O0P4I5851I) (LURASIDONE -		LURAS IDONE HYDROCHLORIDE	:	120 mg
In	active Ingr	edients					
			Ingredient Name			S	trength
CF	ROSCARMELLOS	SE SODIUM (UN	II: M28OL1HH48)				
h	PROMELLOSES	5 (UNII: 3NXW29)	/3WO)				
47	AGNESIUM STE	ARATE (UNII: 70	097M6I30)				
	ANNITOL (UNII: 3						
			ECIFIED (UNII: 3WJQ0SDW1A)				
	TARCH, CORN (U TANIUM DIOXID		<i>•</i> :				
	roduct Char	acteristics	to off-white)	Score		no s	core
Co	roduct Char	acteristics		Score Size		no s 15m	
Cc Sł	roduct Char	white (white	to off-white)		: Code		
Co Sł Fla	r oduct Char blor hape	white (white	to off-white)	Size	: Code	15m	
Ca Sh Fli	r <mark>oduct Char</mark> blor hape avor	white (white	to off-white)	Size	: Code	15m	
Co Sł Fli Co Pi	r oduct Char blor hape avor ontains	white (white OVAL	to off-white)	Size Imprint	: Code keting Start Date	15m 339 Marke	
Co Sh Fli Co Pi	roduct Char blor hape avor bontains ackaging	Pacteristics	to off-white)	Size Imprint Mar	keting Start Date	15m 339 Marke	m eting End
Co Sh Fli Co Pi	roduct Char olor ape avor ontains ackaging Item Code NDC:23155- 891-18 NDC:23155- 891-03	Pa 20000 in 1 COI Product 30 in 1 BOTTLE Product	to off-white) Ickage Description NTAINER; Type 0: Not a Combination E; Type 0: Not a Combination	Size Imprint Mar	keting Start Date 2023	15m 339 Marke	m eting End Date
Co Sh Fli Co Pi #	roduct Char blor hape avor ontains ackaging item Code NDC:23155- 891-03 NDC:23155- 891-03	Pa 20000 in 1 COI Product 20000 in 1 BOTTLE Product 100 in 1 BOTTLE Product	to off-white) Ckage Description NTAINER; Type 0: Not a Combination E; Type 0: Not a Combination E; Type 0: Not a Combination	Mar ¹	keting Start Date 2023 2023	15m 339 Marke D	m eting End pate
C c S F F I i C c P i # 1 2 3 4	roduct Char blor hape avor ontains ackaging item Code NDC:23155- 891-03 NDC:23155- 891-01 NDC:23155- 891-01 NDC:23155- 891-05	Pa 20000 in 1 COI Product 30 in 1 BOTTLE Product 100 in 1 BOTTLE Product 500 in 1 BOTTLE Product	to off-white) Ckage Description NTAINER; Type 0: Not a Combination E; Type 0: Not a Combination	Size Imprint Mar 10/19/2 10/19/2	keting Start Date 2023 2023 2023	15m 339 Marke D 03/30/202	m eting End pate 25
C c S l Fl: C c P i # 1 2 3 4	roduct Char olor hape avor ontains ackaging item Code NDC:23155- 891-18 NDC:23155- 891-03 NDC:23155- 891-01 NDC:23155- 891-01 NDC:23155-	Pa 20000 in 1 COI Product 30 in 1 BOTTLE Product 100 in 1 BOTTLE Product 500 in 1 BOTTLE Product	to off-white) Ckage Description NTAINER; Type 0: Not a Combination E; Type 0: Not a Combination E; Type 0: Not a Combination	Size Imprint Mar 10/19/2 10/19/2	keting Start Date 2023 2023 2023 2023 2023	15m 339 Marke D 03/30/202	m eting End pate 25 25 25
C c Sh Fli C c P i # 1 2 3 4 5	roduct Char blor hape avor ontains ackaging item Code NDC:23155- 891-03 NDC:23155- 891-01 NDC:23155- 891-01 NDC:23155- 891-05 NDC:23155- 891-05 NDC:23155-	Acteristics white (white OVAL OVAL 20000 in 1 COI Product 30 in 1 BOTTLE Product 100 in 1 BOTTLE Product 500 in 1 BOTTLE Product 1000 in 1 BOTTLE Product	to off-white) Ckage Description NTAINER; Type 0: Not a Combination E; Type 0: Not a Combination LE; Type 0: Not a Combination LE; Type 0: Not a Combination FLE; Type 0: Not a Combination	Size Imprint Mari 10/19/2 10/19/2 10/19/2	keting Start Date 2023 2023 2023 2023 2023	15m 339 Marke D 03/30/202 03/30/202	m eting End pate 25 25 25

Labeler - Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Inc. (780779901)

Establishment						
Name	Address	ID/FEI	Business Operations			
Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc.			manufacture(23155-887, 23155-888, 23155-889, 23155-890, 23155- 891) , analysis(23155-887, 23155-888, 23155-889, 23155-890, 23155- 891) , pack(23155-887, 23155-888, 23155-889, 23155-890, 23155- 891)			

Revised: 2/2025

Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Inc.